Download:
pdf |
pdfCenters for Disease Control and Prevention
NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH
PROMOTION
The Innovative Cardiovascular Health Program
CDC-RFA-DP-23-0005
05/23/2023
Table of Contents
A. Funding Opportunity Description ...............................................................................................3
B. Award Information ....................................................................................................................28
C. Eligibility Information ..............................................................................................................29
D. Application and Submission Information .................................................................................30
E. Review and Selection Process ...................................................................................................42
F. Award Administration Information ...........................................................................................47
G. Agency Contacts .......................................................................................................................54
H. Other Information .....................................................................................................................55
I. Glossary ......................................................................................................................................56
Part I. Overview
Applicants must go to the synopsis page of this announcement at www.grants.gov and click on
the "Subscribe" button link to ensure they receive notifications of any changes to CDC-RFA-DP23-0005. Applicants also must provide an e-mail address to www.grants.gov to receive
notifications of changes.
A. Federal Agency Name:
Centers for Disease Control and Prevention (CDC) / Agency for Toxic Substances and Disease
Registry (ATSDR)
B. Notice of Funding Opportunity (NOFO) Title:
The Innovative Cardiovascular Health Program
C. Announcement Type: New - Type 1:
This announcement is only for non-research activities supported by CDC. If research is
proposed, the application will not be considered. For this purpose, research is defined
at https://www.gpo.gov/fdsys/pkg/CFR-2007-title42-vol1/pdf/CFR-2007-title42-vol1-sec522.pdf. Guidance on how CDC interprets the definition of research in the context of public health
can be found at https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr46/index.html (See section 45 CFR 46.102(d)).
D. Agency Notice of Funding Opportunity Number:
CDC-RFA-DP-23-0005
E. Assistance Listings Number:
93.426
Page 1 of 61
F. Dates:
1. Due Date for Letter of Intent (LOI):
04/22/2023
2. Due Date for Applications:
05/23/2023
11:59 p.m. U.S. Eastern Standard Time, at www.grants.gov.
3. Due Date for Informational Conference Call:
The Innovative Cardiovascular Health Program
Applicant Informational Webinar
Tuesday, March 28, 2023 3:00pm - 4:00pm ET
Click the link below to join the webinar:
https://cdc.zoomgov.com/j/1600868630?pwd=Z3BZV0VLaWRiSHp4TlRRcDlYY0E3QT09
Or join by phone:
US: +1 669 254 5252 or
+1 646 828 7666 or
+1 646 964 1167 or
+1 551 285 1373 or
+1 669 216 1590 or
+1 415 449 4000
Webinar ID: 160 086 8630
Passcode: 74072053
Additional information about this and other DHDSP funding opportunities may be found at:
https://www.cdc.gov/dhdsp/funding-opps/index.htm
Programmatic questions about this NOFO may be submitted via email:
InnovativeCVH@cdc.gov
Responses will be posted to the NOFO informational website.
G. Executive Summary:
1. Summary Paragraph
This NOFO focuses on comprehensive efforts to identify and respond to health care disparities in
cardiovascular disease (CVD) and improve related outcomes, specifically for those with
hypertension and high cholesterol.
Page 2 of 61
Proposed interventions must assess and address the disparities and inequities in communities at
highest risk, where there is a particular need for equity-focused health system interventions to
prevent, detect, control, and manage hypertension and high cholesterol.
Populations of focus for this award are adults aged 18 and older with a hypertension crude
prevalence of 53% or higher, as shown by data specifically at the census tract level. Emphasis
should be placed on achieving impact and reach across geographic locations where disparate
populations can benefit from the strategies included in this NOFO. Applicants must provide
details in the Target Population section of the Project Narrative that clearly demonstrate the
methodology and data sources used for identifying the population of focus at the census tract
level. CDC will work with successful applicants post award to offer confirmation and approval
of identified populations through technical assistance with revising workplan, evaluation plan,
and budget.
a. Eligible Applicants:
Open Competition
b. Funding Instrument Type:
CA (Cooperative Agreement)
c. Approximate Number of Awards
12
d. Total Period of Performance Funding:
$105,000,000
e. Average One Year Award Amount:
$950,000
f. Total Period of Performance Length:
5 year(s)
g. Estimated Award Date:
August 30, 2023
h. Cost Sharing and / or Matching Requirements:
No
Part II. Full Text
A. Funding Opportunity Description
1. Background
a. Overview
Unequal socioeconomic conditions and unfair opportunity structures have long existed and
contribute to poor health outcomes in minority and ethnic populations and geographically and
economically disadvantaged communities. Poverty, inferior housing and health care, and other
debilitating social conditions are endemic to some communities, including Non-Hispanic Black
(NHB), Hispanic, and Native American communities.
Research highlights the high prevalence of cardiovascular disease (CVD), including
hypertension, high cholesterol, and stroke in these groups. CVD is the leading cause of death in
the US and stroke is the 5th leading cause with an estimated 1 in 9 health care dollars spent
Page 3 of 61
treating CVD. Despite significant decreases in CVD rates in the last 20 years, NHB continue to
have higher CVD mortality rates than Non-Hispanic Whites (NHW). In 2019, NHB women and
men younger than 65 were 2.0 and 1.3 times more likely to experience premature death from
CVD than their NHW counterparts. In 2020, NHB had the highest heart disease mortality rates at
228.6 per 100,000 and stroke at 56.8 per 100,000.
Uncontrolled hypertension is the primary contributor to morbidity and mortality rate disparities
in CVD between NHB and other racial and ethnic groups. In 2019, NHB had more than double
the age-adjusted death rates (56.7) attributable primarily to hypertension compared to NHW
(25.7).
Of the 1 in 2 US adults with hypertension, only 26.1% have controlled blood pressure. By age
55, the cumulative incidence of hypertension reaches almost 76% in NHB men and women,
compared to 54.5% and 40.0% among NHW men and women, respectively. Moreover, NHB had
a 1.5 to 2 times higher risk for hypertension after adjustment for other factors, regardless of
baseline blood pressure. Among NHB adults who did not report a hypertension diagnosis, a
larger proportion (28%) were unaware of hypertension (BP ≥140/90 mm Hg) compared to NHW
adults (16%). Despite the similar rate of hypertension treatment, only one-third of NHB adults
had their blood pressure controlled, in contrast to 45.0% of NHW adults. These data clearly
indicate that NHB bear the greatest burden of CVD among US adults.
The outcomes are as stark in other CVD-related illnesses. Although the prevalence of high
cholesterol in NHB is comparable to or lower than in NHW, racial-ethnic disparities occur at
every level of diagnosis and management. The disparities present in low screening rates, fewer
prescriptions, and medication adherence. Unsatisfactory control of high cholesterol among NHB
stems from the same adverse social conditions that hinder the control of hypertension.
Interventions must include an understanding of individual and community factors that influence
a healthy diet, losing weight, being physically active, and medication adherence to address the
disparities and inequities. There is a need for equity-focused health system interventions to
prevent, detect, control, and manage hypertension and high cholesterol. Building on lessons from
the previous work, this NOFO focuses on comprehensive efforts to identify and respond to
health care disparities and improve CVD-related outcomes, specifically for those with
hypertension and high cholesterol.
Populations of focus for this NOFO are adults aged 18 and older with a hypertension crude
prevalence of 53% or higher, as shown by data specifically at the census tract level. Emphasis
should be placed on achieving impact and reach across geographic locations where disparate
populations can benefit from the strategies included in this NOFO.
b. Statutory Authorities
This program is authorized by Section 30l(a) of the Public Health Service Act [42] U.S.C.
Section 241(a) 93.426.
c. Healthy People 2030
Healthy People 2030 objectives related to Heart Disease and Stroke:
https://health.gov/healthypeople/objectives-and-data/browse-objectives/heart-disease-andstroke
Page 4 of 61
HDS-01: Improve cardiovascular health in adults
HDS-02: Reduce coronary heart disease deaths
HDS-03: Reduce stroke deaths
HDS-04: Reduce the proportion of adults with high blood pressure
HDS-05: Increase control of high blood pressure in adults
HDS-06: Reduce cholesterol in adults
HDS-07: Increase cholesterol treatment in adults
HDS-D07: Increase the proportion of adults whose risk for atherosclerotic cardiovascular disease
was assessed
d. Other National Public Health Priorities and Strategies
CMS Framework for Health Equity 2022-2032:
https://www.cms.gov/files/document/cms-framework-health-equity.pdf
HHS Equity Action Plan: https://www.hhs.gov/sites/default/files/hhs-equity-actionplan.pdf
HRSA Strategic Plan FY23: https://www.hrsa.gov/about/strategic-plan
Million Hearts® 2027: https://millionhearts.hhs.gov/index.html
The Guide to Community Preventive Services:
https://www.thecommunityguide.org/topics/heart-disease-stroke-prevention.html
The Surgeon General’s Call to Action to Control Hypertension:
https://www.hhs.gov/sites/default/files/call-to-action-to-control-hypertension.pdf
e. Relevant Work
This NOFO builds on the accomplishments and outcomes achieved through the Improving the
Health of Americans Through Prevention and Management of Diabetes and Heart Disease and
Stroke (CDC-RFA-DP18-1815) (https://www.cdc.gov/chronicdisease/about/foa/1815/index.htm)
and the Diabetes and Heart Disease & Stroke Prevent Programs-Innovative State and Local
Public Health Strategies to Prevent and Manage Diabetes and Heart Disease and Stroke (CDCRFA-DP18-1817) (https://www.cdc.gov/chronicdisease/programs-impact/supported/index.htm)
NOFOs.
2. CDC Project Description
a. Approach
Bold indicates period of performance outcome.
Strategies and Activities
Short-Term Outcomes
Intermediate- Long-Term
Term
Outcomes
Outcomes
Page 5 of 61
Strategy 1. Track and Monitor Clinical Measures Shown to
Improve Health and Wellness, and Health Care Quality Within
Approved Populations of Focus with Hypertension and High
Cholesterol.
Improved
blood pressure
control among
populations
1A. Advance the adoption and use Increased use of EHRs and within partner Improved
of electronic health records (EHR) HIT to report, monitor, and health care
cardiovascular
and
and health information technology track clinical data and
health
community
(HIT) to identify, track, and
social services and support
monitor clinical and social
needs to improve detection settings.
Reduced
services and support needs
measures to address health care
disparities and health outcomes
within approved populations of
focus.
of health care disparities
disparities in
and the identification,
cardiovascular
management, and
health
treatment within approved Reduced
populations of focus.
disparities in
blood pressure
1B. Promote the use of
control among
standardized processes or tools, Increased use of
such as GIS or other Geostandardized processes or populations
mapping tools, to identify the
tools, such as GIS or other within partner
health care
social services and support needs Geo-mapping tools, to
within approved populations of identify, assess, track, and and
focus and monitor and assess the address the social services community
settings.
referral and utilization of those
and support needs
services, such as the need for
within approved
transportation, housing, childcare, populations of focus.
etc.
Strategy 2: Implement Team-Based Care to Prevent, Detect,
Control, and Manage Hypertension and High Cholesterol
Within Approved Populations of Focus.
Increased use of health
information systems to
2A. Advance the use of health
support communication
information systems that support
and coordination among
team-based care to monitor and
care team members to
address hypertension and high
monitor and address
cholesterol within approved
hypertension and high
populations of focus.
cholesterol within approved
populations of focus.
Increased
utilization of
social support
services
among
approved
populations of
focus.
Increased use of
2B. Assemble or create
multidisciplinary care
multidisciplinary teams to identify teams adhering to evidencesocial services and support needs based guidelines to address
within approved populations of social services and support
focus.
needs within approved
populations of focus.
Page 6 of 61
2C. Build and manage a
coordinated network of multidisciplinary partnerships that
address identified barriers and
needs within approved
populations of focus, related to
their social services and support
needs (e.g., childcare,
transportation, language
translation, food assistance, and
housing).
Increased multidisciplinary
partnerships that address
identified barriers and
social services and support
needs within approved
populations of focus.
Strategy 3: Link Community Resources and Clinical Services
that Support Comprehensive Bidirectional Referral and FollowUp Systems Aimed at Mitigating Social Services and Support
Barriers for Optimal Health Outcomes Within Approved
Populations of Focus.
3A. Create and enhance
community-clinical links to
identify social determinants of
health {(SDOH) (e.g., housing,
transportation, access to care, and
community resources)} and
respond to the individual social
services and support needs
within approved populations of
focus.
Increased community
clinical links
to identify and respond to
social
support needs within
approved populations of
focus.
3B. Identify and deploy dedicated Increased engagement of
CHWs (or their equivalents) to
CHWs (or their
provide a continuum of care and equivalents) to provide a
services which extend the benefits continuum of care by
of clinical interventions and
extending clinical
address social needs leading to interventions and
optimal health outcomes within addressing social services
approved populations of focus.
and support needs within
approved populations of
focus.
3C. Promote the use of selfmeasured blood pressure
monitoring with clinical support
within approved populations of
focus.
Increased use of SMBP
with clinical support within
approved populations of
focus.
Page 7 of 61
i. Purpose
This NOFO focuses on comprehensive efforts to identify and respond to health care disparities
and improve health outcomes, specifically for those with hypertension and high
cholesterol. Populations of focus for this NOFO are adults aged 18 and older with a
hypertension crude prevalence of 53% or higher, as shown by data specifically at the census
tract level. Emphasis should be placed on achieving impact and reach across geographic
locations where disparate populations can benefit from the strategies included in this NOFO.
ii. Outcomes
Recipients are expected to achieve the following outcomes by the end of the period of
performance:
Short-term outcomes by strategy
Strategy 1:
Increased use of EHRs and HIT to report, monitor, and track clinical data and social
services and support needs to improve detection of health care disparities and the
identification, management, and treatment within approved populations of focus.
Increased use of standardized processes or tools, such as GIS or other Geo-mapping
tools, to identify, assess, track, and address the social services and support needs
within approved populations of focus.
Strategy 2:
Increased use of health information systems to support communication and coordination
among care team members to monitor and address hypertension and high cholesterol
within approved populations of focus.
Increased use of multidisciplinary care teams adhering to evidence-based guidelines to
address social services and support needs within approved populations of focus.
Increased multidisciplinary partnerships that address identified barriers and social
services and support needs within approved populations of focus.
Strategy 3:
Increased community clinical links to identify and respond to social services and support
needs within approved populations of focus.
Increased engagement of CHWs (or their equivalents) to provide a continuum of care by
extending clinical interventions and addressing social services and support needs within
approved populations of focus.
Increased use of SMBP with clinical support within approved populations of focus.
Intermediate outcomes
Improved blood pressure control among populations within partner health care and
community settings.
Reduced disparities in blood pressure control among populations within partner health
care and community settings.
Page 8 of 61
Increased utilization of social support services among approved populations of focus.
iii. Strategies and Activities
Applicants must address all strategies.
Strategy 1. Track and Monitor Clinical Measures Shown to Improve Health and Wellness,
Health Care Quality, and Identify Patients with Hypertension and/ High Cholesterol.
1A: Advance the adoption and use of electronic health records (EHR) and health
information technology (HIT) to identify, track, and monitor clinical and social services
and support needs measures to address health care disparities and health outcomes within
approved populations of focus.
1B: Promote the use of standardized processes or tools, such as GIS or other Geomapping tools, to identify the social services and support needs within approved
populations of focus, and monitor and assess the referral and utilization of those services,
such as the need for transportation, housing, childcare, etc.
Strategy 2: Implement Team-Based Care to Prevent and Reduce CVD Risk with a Focus on
Hypertension and High Cholesterol Prevention, Detection, Control, and Management.
2A: Advance the use of health information systems that support team-based care to
monitor population health with a focus on health disparities, hypertension, and high
cholesterol within approved populations of focus.
2B: Assemble or create multidisciplinary teams to identify social service and support
needs within approved populations of focus.
2C: Build and manage a coordinated network of multidisciplinary partnerships that
address identified barriers and needs within approved populations of focus, related to
their social services and support needs (e.g., childcare, transportation, language
assistance, food assistance, and housing).
Strategy 3: Link Community Resources and Clinical Services that Support Comprehensive
Bidirectional Referral and Follow-Up Systems Aimed at Mitigating Social Support Barriers for
Optimal Health Outcomes.
3A: Create and enhance community-clinical links to identify SDOH (e.g., housing,
transportation, access to care, and community resources) and respond to the individual
social services and support needs within approved populations of focus.
3B: Identify and deploy dedicated CHWs (or their equivalents) to provide a continuum of
care and services which extend the benefits of clinical interventions and address social
services and support needs leading to optimal health outcomes within approved
populations of focus.
3C: Promote the use of self-measured blood pressure monitoring with clinical support
within approved populations of focus.
This NOFO will require recipients to collaborate or partner with a heart disease and stroke
learning collaborative (LC) or similar entity. If one does not exist, recipients will be required to
Page 9 of 61
create an LC. Post-award technical assistance will facilitate connections with existing and new
LCs in a given jurisdiction, including but not limited to the state level LC that is required under
CDC-RFA-DP-23- 0004: The National Cardiovascular Health Program.
An applicant should describe its history of establishing or partnering with multi-sectoral learning
collaboratives (LCs) and collaborating with organizations with a history of working with
approved populations of focus who are impacted by the high prevalence of CVD, with specific
emphasis on hypertension and high cholesterol exacerbated by health inequities and disparities,
social determinants, such as low incomes, poor health care, and unfair opportunity structures.
For the purposes of this NOFO, an LC is defined as a group of public health entities, health care
providers, and community leaders and their partners with experience working to address and
implement evidence-based or evidence-informed practices for CVD prevention, detection,
control, and management within approved priority populations of focus. The applicant must
describe how entities on the LC have a history of collaborating to achieve sustainable change and
improvement in the areas outlined in the NOFO. The LC is expected to facilitate communication
and the exchange of ideas between health systems, community health organizations, and public
health entities. It will leverage technical and financial resources to support programs to improve
cardiovascular health outcomes.
An LC may be an alliance of public health entities, housing, commerce, and transportation
agencies, health systems, health care providers, clinical quality improvement organizations,
health information technology experts, public and private payers, pharmacists, mental and
behavioral health professionals, community-based health care professionals, community
organizations, safety net providers, health departments, tribal organizations and others. These
partners may also directly intervene on a clinical or community basis to address the social
determinants of health (SDOH).
The LC serves as a hub focused on developing innovative approaches to improve overall
cardiovascular health and is equipped to apply those approaches to the mitigation of SDOH and
other associated risk factors within the approved populations of focus.
The goals of a heart disease and stroke learning collaborative are:
Prioritizing populations and communities with the highest prevalence of CVD, with a
focus on advancing health equity.
Serving populations and communities affected disproportionately by CVD, specifically
high blood pressure, high blood cholesterol, or stroke, due to unfair opportunity
structures and SDOH, such as limited access to health care, inadequate or poor quality of
health care, or economic instability.
Achieving optimal health outcomes within the approved populations of focus
To achieve these goals:
Recipients must ensure the LC employs culturally informed, evidence-based, and
evidence-informed interventions and approaches that address social services and support
needs to advance universal health equity goals.
Page 10 of 61
Recipients must be able to document, explain, and report on the effects of efforts to
address the impact of racism and other social injustices on cardiovascular health
outcomes, specifically high blood pressure, high blood cholesterol, and stroke.
Recipients will be required to use Geographic Information System (GIS) mapping technology to
identify and include in the action plan census geographies with priority populations with the
highest prevalence rates and at the highest risk of developing cardiovascular disease. Emphasis
should be placed on achieving impact and reach across geographic locations where disparate
populations can benefit from the strategies included in this NOFO. Recipients will be expected to
design and implement strategies using EHR and HIT to detect and mitigate health care disparities
and utilize quality improvement techniques resulting in optimal health outcomes.
These interdisciplinary partnerships must have a demonstrated history of successfully and
effectively serving the approved populations of focus and their communities, by creating and
enhancing community-clinical links.
The interdisciplinary team must have demonstrated experience in responding to SDOH and
social services and support needs. Referrals must include agencies in the community that serve
the approved population of focus and provide safety net services.
LC partnerships must strengthen efforts to expand care teams to include health care providers,
community health workers, social workers, patient navigators, pharmacists, and other members
of the care team in community settings outside of health care facilities to enhance follow-up,
communication, and coordination among identified communities and populations.
Members of the LC must examine existing policies that are barriers to optimal health outcomes
and engage in mitigation strategies aimed at system-level changes that reduce health and health
care disparities and improve community conditions.
Post award technical assistance provided by CDC will ensure successful applicants adhere to the
requirement for facilitating connections with any relevant existing and new LCs in a given
jurisdiction, including but not limited to the state level LC that is required under CDC-RFA-DP23-0004: The National Cardiovascular Health Program.
Post-award technical assistance provided by CDC to successful applicants will ensure LCs
develop detailed action plans that complement the work plan and lists key partners the first of
which must be in place within the first 90 days, that also lists key partners.
During the Period of Performance, recipients are also charged with ensuring the LC focuses on:
Increasing the percentage of patients 18–85 years of age who have had a hypertension
diagnosis and among those diagnosed, blood pressure was adequately controlled during
the measurement year.
Testing models for collaboration between public health, health care, and community
partners.
Deploying a quality improvement process to affect practice and policy at all levels of the
system.
Page 11 of 61
Ensuring newly established LCs and partnerships with existing LCs have at least 51% of
participating collaborators and partners that have demonstrated history and experience
working with and representing the interests of approved populations of focus.
Ensuring a dedicated staff person is identified, as evidenced by explicit inclusion in the
work plan and budget, who will focus on health inequities and build relationships at the
designated levels to decrease health care disparities and advance health equity.
1. Collaborations
a. With other CDC projects and CDC-funded organizations:
Recipients should establish collaborative, strategic partnerships with other CDC-funded
programs within and outside the state health departments, tribes and tribal organizations and
community-based organizations. This will allow for more efficient use of existing resources.
This also will allow for the exchange of information among experts working in various areas of
public health and other sectors. Recipients are expected to partner, where appropriate, with other
CDC-funded heart disease and stroke programs and initiatives, including but not limited to The
National Cardiovascular Health Program, WISEWOMAN, Paul Coverdell National Acute Stroke
Program, Good Health and Wellness in Indian Country, Community Health Workers for COVID
Response and Resilient Communities, and the Million Hearts® initiative.
Letters of support, memoranda of understanding (MOU), or memoranda of agreement (MOA)
with a firm commitment from providers and partners that outline the relationship, needs, and
resources provided should be included in the application. Applicants should submit letters of
support from organizations and entities that will have a role in helping to achieve specific NOFO
activities and outcomes. Letters must be dated within 45 days of the application. These files
should be named "MOUs/MOAs.applicant name" and uploaded as a PDF file
at www.grants.gov.
b. With organizations not funded by CDC:
An applicant should describe its history of establishing or partnering with multi-sectoral learning
collaboratives (LC) and collaborating with organizations with a history of working with
approved populations of focus who are impacted by the high prevalence of CVD, with specific
emphasis on hypertension and high cholesterol exacerbated by health inequities and disparities,
social determinants, such as low incomes, poor health care, and unfair opportunity structures.
Proposed collaborations must be relevant for all NOFO strategies. These organizations may
include employers, hospitals, non-profit agencies, other federal, state, or local government
agencies, tribes or tribal organizations, professional associations (state medical society, other
medical specialty associations, etc.), quality improvement organizations housing, commerce,
and/or transportation agencies, healthcare providers, health information technology experts,
public and private payers, pharmacists, mental and behavioral health professionals, communitybased health care professionals, community organizations, safety net providers, and others.
Letters of support, memoranda of understanding (MOU), or memoranda of agreement (MOA)
with a firm commitment from providers and partners that outline the relationship, needs, and
resources provided should be included in the application. Applicants must submit letters of
Page 12 of 61
support from organizations and entities that will have a role in helping to achieve specific NOFO
activities and outcomes. Letters must be dated within 45 days of the application. These files must
be named "MOUs/MOAs.applicant name" and uploaded as a PDF file at www.grants.gov.
2. Target Populations
Populations of focus for this NOFO are adults aged 18 and older with a hypertension crude
prevalence of 53% or higher, as shown by data specifically at the census tract
level. Emphasis should be placed on achieving impact and reach across geographic locations
where disparate populations can benefit from the strategies included in this NOFO. Priority
populations should include those affected disproportionately by hypertension and high
cholesterol due to socioeconomic or other factors, including inadequate access to care, poor
quality of care, or low income.
a. Health Disparities
One of the four Healthy People 2030 Foundational Health Measures is eliminating health
disparities. This NOFO will address the challenges and health inequities in chronic disease risk
factors and conditions that populations at high risk for CVD experience. These efforts will help
determine the public health impact of programs intended to improve specific risks, conditions,
and barriers experienced by populations living with high levels of disease burden for high blood
pressure and high cholesterol.
Recipients are expected to advance health equity among priority populations to prevent and
mitigate the impact of heart disease and stroke to improve health outcomes, increase life
expectancy and quality of life within approved populations of focus. Advancing health equity
can be accomplished in part through understanding how health disparities and health inequities
exist within cardiovascular health. Cardiovascular disparities are compounded by variations in
disease rates and the effects of unfair opportunity structures which influence social determinants
of health. Some of these effects include but are not limited to lack of access to preventive and
treatment services among racial and ethnic minority populations and geographically and
economically disadvantaged communities.
An applicant must offer a plan that prioritizes eliminating CVD health disparities and advancing
health equity in these locations. The plan must describe the health equity challenges in these
locations, detail proposals to address those challenges through various strategies and show how
progress will be measured. Applicants should also describe how they propose to engage
communities in these locations, influence the environments, and empower individuals so that
services are accessible and culturally appropriate. Organizations serving the population, and
representatives of the population, should be engaged in planning processes.
iv. Funding Strategy
Funding provided will range from $650,000 to $1,200,000, with an average award of $950,000.
Award amounts will be based on priority populations which for this NOFO are adults aged 18
and older with a hypertension crude prevalence of 53% or higher, as shown by data specifically
at the census tract level. Consideration of the geographic area where work is proposed, along
with prior experience and organizational capacity.
b. Evaluation and Performance Measurement
i. CDC Evaluation and Performance Measurement Strategy
Page 13 of 61
Evaluation and performance measurement help demonstrate program accomplishments,
strengthen the evidence for strategy implementation, and guide program improvement for CDC
and recipients.
Throughout the five-year period of performance, CDC will work individually and collectively
with recipients to track the implementation of recipient strategies and activities and assess
progress on achieving the five-year NOFO outcomes. Both the process and outcome evaluation
will seek to answer the following overarching evaluation questions:
Process (Implementation Evaluation):
1. To what extent have recipients increased the reach of program strategies to improve
cardiovascular disease within approved populations of focus?
2. What factors or components were associated with effective implementation of program
strategies and learning collaboratives?
3. What factors were associated with identifying and addressing social services and support
needs and social determinants of health within approved populations of focus?
Outcome Evaluation:
1. To what extent have the implemented strategies and learning collaboratives contributed
to a measurable change in health outcomes within approved populations of focus?
2. What innovative strategies implemented by recipients can be replicated and/or scaled?
CDC will use an evaluation approach that facilitates recipient-conducted rigorous evaluations of
innovative strategies, as well as collection and reporting of data that assess the program across
recipients. This will include (1) ongoing monitoring and evaluation through the collection and
reporting of performance measures, (2) a CDC-led comprehensive evaluation, and (3) recipientled evaluations.
Performance measures developed for this program correspond to the strategies and outcomes
described in the logic model. Recipients will report all short-term and intermediate performance
measures. Recipients are not required to report long term measures. CDC will work with
recipients on operationalizing and further defining each performance measure, and guidance will
be provided prior to the first reporting period. Performance measures will be reported semiannually to CDC; and CDC will manage and analyze the data to assess recipient program
progress, respond to broader technical assistance needs, and report to funders, recipients, and
partners. CDC will analyze performance measure data semi-annually and develop aggregate
performance measure reports to be disseminated to recipients and other key partners, including
federal partners, non-funded partners, and policymakers, as appropriate. These aggregate
findings may also be presented during site visits and recipient meetings. In addition to
performance measures reported by recipients, CDC will track additional measures relevant to the
program through national datasets or national evaluation activities.
For the CDC-led comprehensive evaluation activities, CDC will lead the design, data collection,
analysis, and reporting. CDC will engage recipients in developing and implementing the
evaluation and recipients will be asked to participate in national evaluation activities such as
surveys, interviews, case studies, and other data collection efforts. Recipients may also be asked
Page 14 of 61
to participate in special studies led by CDC that further explore specific components of the
program or across DHDSP-funded programs. An appropriate level of guidance and support will
be provided to the recipients to ensure their effective participation in the comprehensive
evaluation. CDC will use findings from these evaluation efforts to refine its technical assistance
and, in turn, maximize and sustain program outcomes. Evaluation findings will be shared with
recipients on a regular basis.
For recipient-led evaluations, CDC will assist recipients in developing and implementing
evaluation plans that are useful for recipient program improvement and for the overall evaluation
of the program. Recipients will be expected to conduct rigorous evaluations that will
demonstrate their progress addressing the health and social services and support needs within
approved populations of focus.
For all components of the evaluation, CDC and recipients will only collect data that will be
analyzed and used. CDC will provide evaluation technical assistance and ongoing evaluation
guidance on recipient-level evaluation and performance measures. Evaluation technical
assistance will be provided using a customized approach to ensure that tools and services
provided meet the needs of the recipients. All data will be reported via a secure system. All
evaluation findings produced by CDC and recipients will contribute to: continuous program and
quality improvement of program efforts, the evidence base, documentation and sharing of
lessons learned to support replication and scaling of program strategies, and future funding
opportunities supported by CDC.
The data collected by CDC for performance measurement and evaluation are directly related to
the implementation of the strategies and/or the desired outcomes indicated in the logic model and
do not include any personally identifiable information. Data being collected are strictly related to
the implementation of the NOFO strategies and shall be used for assessing and reporting
progress and for other pertinent program improvement actions. Recipients will report
performance measure data semi-annually and will only have access to their data. Over the fiveyear period of performance, data will be secured with limited access to authorized CDC program
and evaluation staff to the extent allowed under applicable Federal law. CDC will aggregate data
across all recipients to publish regular reports. Applicants should submit a Data Management
Plan (DMP). A template provided by NCCDPHP can be found
at https://www.cdc.gov/chronicdisease/programs-impact/nofo/index.htm. Applicants are not
required to use the sample template; however, all elements included in the template must be
addressed.
The table below aligns with the logic model and shows the relationship between the
overarching focus areas, specific strategies, outcomes and performance measures.
Recipients are required to address all strategies and report all short term and intermediate
performance measures.
Strategies
Short-Term Outcomes and Performance
Measures
Page 15 of 61
Strategy 1. Track and Monitor Clinical Measures Shown to Improve Health and Wellness, and
Health Care Quality Within Approved Populations of Focus, and Identify Patients with
Hypertension and High Cholesterol.
Increased use of EHRs and HIT to report,
monitor, and track clinical data and social
services and support needs to improve
1A. Advance the adoption and use of electronic detection of health care disparities and the
health records (EHR) and health information
identification, management, and treatment
technology (HIT) to identify, track, and monitor within approved populations of focus.
clinical and social services and support needs
Measure 1A:
measures to address health care disparities and
health outcomes within approved populations of # and % of clinics or health care systems that
have policies/protocols in place requiring the
focus.
use of EHRs and standardized clinical quality
measures to track hypertension control
measures by race, ethnicity, and other
populations of focus.
1B. Promote the use of standardized processes or Increased use of standardized processes or
tools, such as GIS or other Geo-mapping tools, to tools, such as GIS or other Geo-mapping
tools, to identify, assess, track, and address
identify the social services and support needs
within approved populations of focus and monitor the social services and support needs within
approved populations of focus.
and assess the referral and utilization of those
services, such as the need for transportation,
Measure 1B:
housing, childcare, etc.
# and % of clinics or health care systems that
use standardized processes or tools to
identify, assess, track, and address the social
services support needs within approved
populations of focus.
Strategy 2: Implement Team-Based Care to Prevent, Detect, Control and Manage Hypertension
and High Cholesterol Within Approved Populations of Focus.
2A. Advance the use of health information
Increased use of health information systems
systems that support team-based care to monitor to support communication and coordination
and address hypertension and high cholesterol
among care team members to monitor and
within approved populations of focus.
address hypertension and high cholesterol
within approved populations of focus.
Measure 2A:
# and % of clinics or health systems that have
policies or protocols in place requiring the
use of clinical data from EHRs or HIT to
support communication within the care team
to coordinate care for hypertension and high
cholesterol within approved populations of
focus.
Page 16 of 61
Increased use of multidisciplinary care
teams adhering to evidence-based guidelines
to address social services and support needs
within approved populations of focus.
2B. Assemble or create multidisciplinary teams to
identify social services and support needs
Measure 2B:
within approved populations of focus.
# of adults, within approved populations of
focus, served by clinics or health systems that
use multidisciplinary care teams that adhere
to evidence-based guidelines.
2C. Build and manage a coordinated network of
multidisciplinary partnerships that address
identified barriers and needs within approved
populations of focus, related to their social
services and support needs (e.g., childcare,
transportation, language translation, food
assistance, and housing).
Increased multidisciplinary partnerships
that address identified barriers and social
services and support needs within approved
populations of focus.
Measure 2C:
# and type of social services within the
recipient's network that address social needs
within approved population of focus.
Strategy 3: Link Community Resources and Clinical Services that Support Comprehensive
Bidirectional Referral and Follow-Up Systems Aimed at Mitigating Social Services and Support
Barriers for Optimal Health Outcomes Within Approved Populations of Focus.
3A. Create and enhance community-clinical links Increased community clinical links to
to identify social determinants of health {(SDoH) identify and respond to social services and
e.g., housing, transportation, access to care, and support needs within approved populations
community resources} and respond to the
of focus.
individual social services and support needs
Measure 3A:
within approved populations of focus.
# of adults within approved populations of
focus, who are referred to lifestyle change
programs or social services and support..
3B. Identify and deploy dedicated CHWs (or their Increased engagement of CHWs (or their
equivalents) to provide a continuum of care and equivalents) to provide a continuum of care
services which extend the benefits of clinical
by extending clinical interventions and
interventions and address social services and
addressing social services and support needs
support needs leading to optimal health outcomes within approved populations of focus.
Page 17 of 61
within approved populations of focus.
Measure 3B:
# of CHWs (or their equivalent) who engage
with community organizations to provide a
continuum of care by extending clinical
interventions and addressing social services
and support needs within approved
populations of focus.
Increased use of SMBP with clinical
support within approved populations of
focus.
3C. Promote the use of self-measured blood
pressure monitoring with clinical support within
approved populations of focus
Measure 3C:
# of adults within approved populations of
focus who participate in SMBP with clinical
support.
Intermediate Outcomes
Intermediate Required Performance Measures
Improved blood pressure control
# and % of adults within partner health care and
among populations within partner
community settings with known hypertension who have
health care and community
achieved or are currently maintaining blood pressure
settings.
control.
# and % of adults within partner health care and
Reduced disparities in blood
community settings, reported by race, ethnicity, and
pressure control among
approved population of focus, with known hypertension
populations within partner health
who have achieved or are currently maintaining blood
care and community settings.
pressure control.
Increased utilization of social and
# and % of adults, within approved populations of focus,
support services within
who were referred to social support services and accessed
populations of focus with
those services.
hypertension and high cholesterol.
ii. Applicant Evaluation and Performance Measurement Plan
Applicants must provide an evaluation and performance measurement plan that demonstrates
how the recipient will fulfill the requirements described in the CDC Evaluation and Performance
Measurement and Project Description sections of this NOFO. At a minimum, the plan must
describe:
Page 18 of 61
How the applicant will collect the performance measures, respond to the evaluation
questions, and use evaluation findings for continuous program quality improvement.
How key program partners will participate in the evaluation and performance
measurement planning processes.
Available data sources, feasibility of collecting appropriate evaluation and performance
data, and other relevant data information (e.g., performance measures proposed by the
applicant)
Plans for updating the Data Management Plan (DMP) as new pertinent information
becomes available. If applicable, throughout the lifecycle of the project. Updates to
DMP should be provided in annual progress reports. The DMP should provide a
description of the data that will be produced using these NOFO funds; access to data;
data standards ensuring released data have documentation describing methods of
collection, what the data represent, and data limitations; and archival and long-term data
preservation plans. For more information about CDC’s policy on the DMP,
see https://www.cdc.gov/grants/additional-requirements/ar-25.html.
Where the applicant chooses to, or is expected to, take on specific evaluation studies, the
applicant should be directed to:
Describe the type of evaluations (i.e., process, outcome, or both).
Describe key evaluation questions to be addressed by these evaluations.
Describe other information (e.g., measures, data sources).
Recipients will be required to submit a more detailed Evaluation and Performance Measurement
plan, including a DMP, if applicable, within the first 6 months of award, as described in the
Reporting Section of this NOFO.
In addition, to enable the required rigorous evaluations, recipients will identify relevant measures
and previously untapped data sources (e.g., health system, electronic health record systems,
surveys, etc.), and where appropriate, develop partnerships to enhance current data systems to
improve the comprehensiveness of monitoring approaches.
The applicant's evaluation and performance measurement plans should:
Ensure that the evaluation questions align with the purpose of this NOFO to improve
hypertension control within approved populations of focus.
Describe an evaluation design that is rigorous enough to clearly document the innovative
approaches to the proposed strategies and the contribution of the strategies to outcomes
outlined in the logic model. This design should include a clear description of indicators,
data sources, data collection methods, analysis plans, and dissemination activities.
Describe access to performance measure data (e.g., hypertension control within approved
populations of focus) and how the applicant will meet the requirements to report
performance measure data to CDC semiannually.
Page 19 of 61
Describe how and how much of the total funding will be allocated to evaluation and
performance measurement. CDC strongly recommends allocating at least 15% to
evaluation and performance measurement.
Describe how GIS is used to identify populations of focus in census geographies
disproportionately impacted by cardiovascular disease.
Recipients are required to work with professional evaluators (either internal or external) to meet
the evaluation and performance reporting requirements of this NOFO by identifying these efforts
in the workplan, evaluation plans, and budget. Therefore, CDC strongly recommends allocating
at least 15% of the total funding award to evaluation and performance monitoring and to
consider both development and implementation costs. For information on developing an
evaluation plan, please refer to the CDC Framework for Program Evaluation in Public Health
(Centers for Disease Control and Prevention. Framework for Program Evaluation in Public
Health. MMWR 1999; 48, No. RR-11. Available
at: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr4811a1.htm).
For the detailed Evaluation and Performance Measurement Plan due 6 months after award, CDC
will work closely with recipients to develop the detailed plan to ensure that it is appropriate for
the activities undertaken and in compliance with the monitoring and evaluation guidance
established by CDC or other guidance otherwise applicable to this cooperative agreement. CDC
will provide additional guidance for developing the Evaluation and Performance Measurement
Plan.
c. Organizational Capacity of Recipients to Implement the Approach
Applicants must describe their organizational capacity to carry out all the strategies outlined in
the Activities and Strategies section. CDC expects all applicants to demonstrate sufficient
organizational capacity and readiness to address and implement the required strategies and
demonstrate impact over the 5-year period of performance.
Organizational Capacity
Applicants must:
Describe how they will coordinate efforts with other publicly- and privately-funded
programs within the state to leverage resources and maximize reach and impact to
address SDOH and social services and support needs related to CVD within approved
populations of focus.
Describe their capacity to manage programs and resources ensuring the administrative,
financial, and staff support necessary to sustain activities. This includes describing an
adequate staffing plan, providing CVs or resumes for proposed personnel, a description
of how program performance will be monitored and how the program will be adjusted to
address identified challenges, an organizational chart, and a project management structure
that clearly defines staff roles and reporting structure as it applies to this funding
opportunity. These files must be named “CVs/Resumes” and “Organizational Charts”
respectively and upload them as PDFs in grants.gov.
Page 20 of 61
Describes a dedicated staff person explicitly included in the work plan and budget, who
will focus on health inequities and build relationships at the designated levels to decrease
health care disparities and advance health equity.
Describe their previous experience working with organizations to implement
interventions within approved populations of focus.
Describe their proposed program plan that demonstrates the ability to document and
disseminate evaluation findings, outcomes, and recommendations, including the
outcomes and achievements resulting from collaborative work with partners.
d. Work Plan
Applicants must submit a detailed work plan for Year 1 of the award and provide a
general summary of work plan activities for Years 2–5.
The work plan must describe how the applicant will address all strategies to achieve NOFO
outcomes. These activities must be in alignment with the NOFO logic model and should include
the required performance measures for accomplishing tasks. Baselines, targets for first reporting
period (6 months), and data sources should be provided for all performance measures (short-term
and intermediate)
A sample work plan format is provided below. Applicants are not required to use the sample
work plan format but are required to include all the elements. Applicants must name this file
“Workplan_Name of Applicant” and upload it as a PDF file. CDC will provide feedback and
technical assistance to award recipients to finalize the work plan activities post-award. The work
plan is not included in the 20-page limit.
Sample DP-23-0005 Work Plan format
Strategy 1. Track and Monitor Clinical Measures Shown to Improve Health and
Wellness and, Health Care Quality Within Approved Populations of Focus, and
Identify Patients with Hypertension and High Cholesterol.
1A: Advance the adoption and use of electronic health records (EHR) and health
information technology (HIT) to identify, track, and monitor clinical and social services
and support needs measures to address health care disparities and health outcomes within
approved populations of focus.
Activities
Respons Start
ible
Date
/
Comp
Position/ letion Date
Party
Short Term Performance Outcome
Short Term Performance Measures
Page 21 of 61
Increased use of EHRs and HIT to report,
monitor, and track clinical data and
social services and support needs to
improve detection of health care
disparities and the identification,
management, and treatment
within approved populations of focus.
Measure 1A: # and % of clinics or health care
systems that have policies/protocols in place
requiring the use of EHRs and standardized
clinical quality measures to track hypertension
control measures by race, ethnicity, and other
populations of focus.
1B:Promote the use of standardized processes or tools, such as GIS or other Geo-mapping
tools, to identify the social services and support needs within approved populations of
focus, and monitor and assess the referral and utilization of those services, such as the
need for transportation, housing, childcare, etc.
Activities
Respons Start
ible
Date
/
Co
Position/ mpletion Date
Party
Short Term Performance Outcome
Increased use of standardized processes
or tools, such as GIS or other Geomapping tools, to identify, assess, track,
and address the social services and
support needs within approved
populations of focus.
Short Term Performance Measure
Measure 1B: # and % of clinics or health care
systems that use standardized processes or
tools to identify, assess, track, and address the
social services support needs within approved
populations of focus.
Strategy 2: Implement Team-Based Care to Prevent, Detect, Control, and Manage
Hypertension and High Cholesterol Within Approved Populations of Focus.
2A: Advance the use of health information systems that support team-based care to
monitor and address hypertension and high cholesterol within approved populations of
focus.
Activities
Respons Start
ible
Date
/
Co
Position/ mpletion Date
Party
Short Term Outcome
Increased use of health information
systems to support communication and
Short Term Performance Measure
Measure 2A: # and % of clinics or health
systems that have policies/protocols in place
Page 22 of 61
coordination among care team members
to monitor and address hypertension and
high cholesterol within approved
populations of focus.
requiring the use of clinical data from EHRs or
HIT to support communication within the care
team to coordinate care for hypertension and
high cholesterol within approved populations
of focus.
2B: Assemble or create multidisciplinary teams to identify social services and support
needs within approved populations of focus.
Activities
Respons Start
ible
Date
/
Co
Position/ mpletion Date
Party
Short Term Outcome
Short Term Performance Measure
Increased use of multidisciplinary care
Measure 2B: # of adults, within approved
teams adhering to evidence-based
populations of focus, served by clinics or
guidelines to address social services and
health systems that use multidisciplinary care
support needs within approved
teams that adhere to evidence-based
populations of focus.
guidelines.
2C: Build and manage a coordinated network of multidisciplinary partnerships that
address identified barriers and needs within approved populations of focus, related to their
social services and support needs (e.g., childcare, transportation, language translation,
food assistance, and housing).
Activities
Respons Start
ible
Date
/
Com
Position/ pletion Date
Party
Short Term Outcome
Increased multidisciplinary partnerships
that address identified barriers and social
services and support needs within
approved populations of focus.
Short Term Performance Measure
Measure 2C: # and type of social services
within the recipient's network that address
social needs within approved population of
focus.
Strategy 3: Link Community Resources and Clinical Services that Support
Comprehensive Bidirectional Referral and Follow-Up Systems Aimed at Mitigating
Social Services and Support Barriers for Optimal Health Outcomes Within Approved
Populations of Focus.
Page 23 of 61
3A: Create and enhance community-clinical links to identify social determinants of health
{(SDoH) e.g., housing, transportation, access to care, and community resources} and
respond to the individual social services and support needs within or approved populations
of focus.
Activities
Respons Start
ible
Date
/
Completion
Position/ Date
Party
Short Term Outcome
Short Term Performance Measure
Increased community clinical links to
Measure 3A: # adults within approved
identify and respond to social services
populations of focus, who are referred to
and support needs within approved
lifestyle change programs or social services
populations of focus.
and support.
3B: Identify and deploy dedicated CHWs (or their equivalents) to provide a continuum of
care and services which extend the benefits of clinical interventions and address social
services and support needs leading to optimal health outcomes within approved
populations of focus.
Activities
Respons Start
ible
Date
/
Completion
Position/ Date
Party
Short Term Outcome
Short Term Performance Measure
Increased engagement of CHWs (or their Measure 3B: # of CHWs (or their equivalent)
equivalents) to provide a continuum of
who engage with community organizations to
care by extending clinical interventions
provide a continuum of care by extending
and addressing social services and
clinical interventions and addressing social
support needs within approved
services and support needs within approved
populations of focus.
populations of focus.
3C: Promote the use of self-measured blood pressure monitoring with clinical support
within approved populations of focus.
Activities
Respons Start
ible
Date
/
Completion
Position/ Date
Party
Page 24 of 61
Short Term Outcome
Short Term Performance Measure
Increased use of SMBP with clinical
Measure 3C: # of adults within approved
support to promote self-management
populations of focus who participate in SMBP
within approved populations of focus.
with clinical support.
Years 2-5
Provide a general summary of work plan activities that address Strategy 3 proposed for
Years 2-5 (maximum of one page narrative).
Intermediate Outcomes
Improved blood pressure control among populations
within partner health care and community settings.
Reduced disparities in blood pressure control among
populations within partner health care and
community settings.
Increased utilization of social support services
among approved populations of focus.
Intermediate Required
Performance Measures
# and % of adults within partner
health care and community settings
with known hypertension who have
achieved or are currently
maintaining blood pressure control.
# and % of adults within partner
health care and community
settings, reported by race,
ethnicity, and approved population
of focus, with known hypertension
who have achieved or are currently
maintaining blood pressure control.
# and % of adults, within approved
populations of focus, who were
referred to social support services
and accessed those services.
e. CDC Monitoring and Accountability Approach
Monitoring activities include routine and ongoing communication between CDC and recipients,
site visits, and recipient reporting (including work plans, performance, and financial reporting).
Consistent with applicable grants regulations and policies, CDC expects the following to be
included in post-award monitoring for grants and cooperative agreements:
Tracking recipient progress in achieving the desired outcomes.
Ensuring the adequacy of recipient systems that underlie and generate data reports.
Creating an environment that fosters integrity in program performance and results.
Page 25 of 61
Monitoring may also include the following activities deemed necessary to monitor the award:
Ensuring that work plans are feasible based on the budget and consistent with the intent
of the award.
Ensuring that recipients are performing at a sufficient level to achieve outcomes
within stated timeframes.
Working with recipients on adjusting the work plan based on achievement of
outcomes, evaluation results and changing budgets.
Monitoring performance measures (both programmatic and financial) to assure
satisfactory performance levels.
Monitoring and reporting activities that assist grants management staff (e.g., grants management
officers and specialists, and project officers) in the identification, notification, and management
of high-risk recipients.
The proposed work plan will be reviewed annually by the project officer and performance
measures will be reviewed semi-annually by the evaluation staff. Monitoring will occur routinely
through ongoing communication between CDC and recipients via monthly calls, reporting
mechanisms (i.e., work plans, performance measures, and financial reporting), and site visits.
Post-award cooperative agreement monitoring and provision of technical assistance and training
will include:
· Ensuring that work plans are feasible, fiscally responsible, consistent with the intent of the
NOFO, and have acceptable milestones and timelines.
· Ensuring that the activities outlined in the NOFO are being completed.
· Assisting recipients in adjusting work plan activities based on achievement of objectives and/or
budget changes.
· Communicating as needed, or at minimum monthly, with the project coordinator and other
program staff on conference calls/webinars.
· Sponsoring webinars and other meetings/trainings associated with the NOFO.
· Providing tools/resources aligned with program activities and NOFO outcomes, assessment,
and implementation support.
CDC will analyze performance measurement data to review progress and identify technical
assistance needs for all NOFO strategies on a semi-annual basis. The performance measure data
will be triangulated with other internal and external sources of appropriate data to arrive at a
rational assessment of progress. Findings from the semi-annual analysis of performance measure
data will be used to identify areas of program improvement, broader technical assistance needs,
and for accountability reporting. CDC will develop semi-annual, aggregate performance measure
reports to be disseminated to recipients and other key partners including federal partners, other
funded and non-funded partners, policy makers, and the public, as appropriate. These aggregate
findings may also be presented during site visits and recipient meetings. In addition to
Page 26 of 61
performance measures reported by recipients, CDC will track other measures that are relevant to
the program through national datasets or national evaluation activities.
f. CDC Program Support to Recipients
The CDC programs supporting this NOFO will be substantially involved beyond site visits and
regular performance and financial monitoring during the period of performance. Substantial
involvement means that the recipient can expect federal programmatic partnership in carrying
out efforts under the award.
CDC will work in partnership with the recipient to ensure the success of the cooperative
agreement by:
Supporting recipients in implementing cooperative agreement requirements and meeting
program outcomes.
Assisting recipients in advancing program activities to achieve project outcomes.
Providing scientific subject matter expertise and resources in support of the required
strategies.
Collaborating with recipients to develop and implement evaluation plans that align with
CDC evaluation activities.
Providing technical assistance on recipients’ evaluation and performance measurement
plans.
Providing technical assistance to define and operationalize performance measures and
reports.
Engaging in and facilitating varied means of communication and peer sharing
opportunities among recipients and with CDC to communicate and share tools and
resources.
Establishing learning opportunities to facilitate the sharing of information among
recipients.
Providing professional development and training opportunities – either in person or
through virtual, web-based training formats – for the purpose of sharing the latest
science, best practices, success stories, and program models.
Participating in relevant meetings, committees, conference calls, and working groups
related to the cooperative agreement requirements to achieve outcomes.
Coordinating communication and program links with other CDC programs and federal
agencies, such as the Health Resources and Services Administration (HRSA), Centers for
Medicare & Medicaid Services (CMS), Indian Health Service (IHS), and the National
Institutes of Health (NIH), as appropriate.
Page 27 of 61
Providing surveillance technical assistance and state-specific data collected by CDC.
Providing technical expertise to other CDC programs and Federal agencies on how to
interface with recipients.
Translating and disseminating lessons learned through publications, meetings, and other
means on promising and best practices to expand the evidence base.
B. Award Information
1. Funding Instrument Type:
CA (Cooperative Agreement)
CDC's substantial involvement in this program appears in the CDC Program Support to
Recipients Section.
2. Award Mechanism:
U58
3. Fiscal Year:
2023
4. Approximate Total Fiscal Year Funding:
$14,400,000
5. Total Period of Performance Funding:
$105,000,000
This amount is subject to the availability of funds.
Estimated Total Funding:
$110,000,000
6. Total Period of Performance Length:
5 year(s)
year(s)
7. Expected Number of Awards:
12
8. Approximate Average Award:
$950,000
Per Budget Period
9. Award Ceiling:
$1,200,000
Per Budget Period
This amount is subject to the availability of funds.
Page 28 of 61
10. Award Floor:
$650,000
Per Budget Period
11. Estimated Award Date:
August 30, 2023
12. Budget Period Length:
12 month(s)
Throughout the project period, CDC will continue the award based on the availability of funds,
the evidence of satisfactory progress by the recipient (as documented in required reports), and
the determination that continued funding is in the best interest of the federal government. The
total number of years for which federal support has been approved (project period) will be shown
in the “Notice of Award.” This information does not constitute a commitment by the federal
government to fund the entire period. The total period of performance comprises the initial
competitive segment and any subsequent non-competitive continuation award(s).
13. Direct Assistance
Direct Assistance (DA) is not available through this NOFO.
If you are successful and receive a Notice of Award, in accepting the award, you agree that the
award and any activities thereunder are subject to all provisions of 45 CFR part 75, currently in
effect or implemented during the period of the award, other Department regulations and policies
in effect at the time of the award, and applicable statutory provisions.
C. Eligibility Information
1. Eligible Applicants
Eligibility Category:
00 (State governments)
01 (County governments)
02 (City or township governments)
04 (Special district governments)
05 (Independent school districts)
06 (Public and State controlled institutions of higher education)
07 (Native American tribal governments (Federally recognized))
08 (Public housing authorities/Indian housing authorities)
11 (Native American tribal organizations (other than Federally recognized tribal governments))
12 (Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher
education)
Page 29 of 61
13 (Nonprofits without 501(c)(3) status with the IRS, other than institutions of higher education)
20 (Private institutions of higher education)
22 (For profit organizations other than small businesses)
23 (Small businesses)
25 (Others (see text field entitled "Additional Information on Eligibility" for clarification))
99 (Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field
entitled "Additional Information on Eligibility")
Additional Eligibility Category:
Government Organizations:
State governments or their bona fide agents (includes the District of Columbia)
Local governments or their bona fide agents
Territorial governments or their bona fide agents in the Commonwealth of Puerto Rico, the
Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam,
the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of
Palau
State controlled institutions of higher education
American Indian or Alaska Native tribal governments (federally recognized or state-recognized)
Non-government Organizations
American Indian or Alaska native tribally designated organizations
2. Additional Information on Eligibility
N/A
3. Justification for Less than Maximum Competition
N/A
4. Cost Sharing or Matching
Cost Sharing / Matching Requirement:
No
5. Maintenance of Effort
Maintenance of effort is not required for this program.
D. Application and Submission Information
1. Required Registrations
An organization must be registered at the three following locations before it can submit an
application for funding at www.grants.gov.
Page 30 of 61
PLEASE NOTE: Effective April 4, 2022, applicants must have a Unique Entity Identifier
(UEI) at the time of application submission (SF-424, field 8c). The UEI is generated as part of
SAM.gov registration. Current SAM.gov registrants have already been assigned their UEI and
can view it in SAM.gov and Grants.gov. Additional information is available on the GSA website,
SAM.gov, and Grants.gov- Finding the UEI.
a. Unique Entity Identifier (UEI):
All applicant organizations must obtain a Unique Entity Identifier (UEI) number by registering
in SAM.gov prior to submitting an application. A UEI number is a unique twelve-digit
identification number assigned to the registering organization.
If funds are awarded to an applicant organization that includes sub-recipients, those subrecipients must provide their UEI numbers before accepting any funds.
b. System for Award Management (SAM):
The SAM is the primary registrant database for the federal government and the repository into
which an entity must submit information required to conduct business as a recipient. All
applicant organizations must register with SAM, and will be assigned a SAM number and a
Unique Entity Identifier (UEI). All information relevant to the SAM number must be current at
all times during which the applicant has an application under consideration for funding by CDC.
If an award is made, the SAM information must be maintained until a final financial report is
submitted or the final payment is received, whichever is later. The SAM registration process can
require 10 or more business days, and registration must be renewed annually. Additional
information about registration procedures may be found at SAM.gov and the SAM.gov
Knowledge Base.
c. Grants.gov:
The first step in submitting an application online is registering your organization
at www.grants.gov, the official HHS E-grant Web site. Registration information is located at the
"Applicant Registration" option at www.grants.gov.
All applicant organizations must register at www.grants.gov. The one-time registration process
usually takes not more than five days to complete. Applicants should start the registration
process as early as possible.
Step System
1
Requirements
Duration
Follow Up
System for 1. Go to SAM.gov and designate
3-5 Business Days but up
Award
an E-Biz POC (You will need to to 2 weeks and must be
Management have an active SAM account
renewed once a year
(SAM)
before you can register on
For SAM
Customer
Service
Contact https://
fsd.gov/ fsdgov/
Page 31 of 61
grants.gov). The UEI is generated
as part of your registration.
home.do Calls:
866-606-8220
1. Set up an individual account in
Grants.gov using organization's
new UEI number to become an
Authorized
It takes one day (after you
Organization Representative
enter the EBiz POC name
(AOR)
Register early!
and EBiz POC email in
2. Once the account is set up the SAM) to receive a UEI
2
Grants.gov
Applicants can
E-BIZ POC will be notified via
(SAM) which will allow
register within
email
you to register with
minutes.
3. Log into grants.gov using the Grants.gov and apply for
password the E-BIZ POC received federal funding.
and create new password
4. This authorizes the AOR to
submit applications on behalf of
the organization
2. Request Application Package
Applicants may access the application package at www.grants.gov.
3. Application Package
Applicants must download the SF-424, Application for Federal Assistance, package associated
with this notice of funding opportunity at www.grants.gov.
4. Submission Dates and Times
If the application is not submitted by the deadline published in the NOFO, it will not be
processed. Office of Grants Services (OGS) personnel will notify the applicant that their
application did not meet the deadline. The applicant must receive pre-approval to submit a paper
application (see Other Submission Requirements section for additional details). If the applicant is
authorized to submit a paper application, it must be received by the deadline provided by OGS.
a. Letter of Intent Deadline (must be emailed)
Number Of Days from Publication 30
04/22/2023
b. Application Deadline
Due Date for Applications 05/23/2023
05/23/2023
11:59 pm U.S. Eastern Time, at www.grants.gov. If Grants.gov is inoperable and cannot receive
applications, and circumstances preclude advance notification of an extension, then applications
must be submitted by the first business day on which Grants.gov operations resume.
Due Date for Information Conference Call
Page 32 of 61
The Innovative Cardiovascular Health Program
Applicant Informational Webinar
Tuesday, March 28, 2023 3:00pm - 4:00pm ET
Click the link below to join the webinar:
https://cdc.zoomgov.com/j/1600868630?pwd=Z3BZV0VLaWRiSHp4TlRRcDlYY0E3QT09
Or join by phone:
US: +1 669 254 5252 or
+1 646 828 7666 or
+1 646 964 1167 or
+1 551 285 1373 or
+1 669 216 1590 or
+1 415 449 4000
Webinar ID: 160 086 8630
Passcode: 74072053
Additional information about this and other DHDSP funding opportunities may be found at:
https://www.cdc.gov/dhdsp/funding-opps/index.htm
Programmatic questions about this NOFO may be submitted via email:
InnovativeCVH@cdc.gov
Responses will be posted to the NOFO informational website.
5. Pre-Award Assessments
Risk Assessment Questionnaire Requirement
CDC is required to conduct pre-award risk assessments to determine the risk an applicant poses
to meeting federal programmatic and administrative requirements by taking into account issues
such as financial instability, insufficient management systems, non-compliance with award
conditions, the charging of unallowable costs, and inexperience. The risk assessment will include
an evaluation of the applicant’s CDC Risk Questionnaire, located
at https://www.cdc.gov/grants/documents/PPMR-G-CDC-Risk-Questionnaire.pdf, as well as a
review of the applicant’s history in all available systems; including OMB-designated repositories
of government-wide eligibility and financial integrity systems (see 45 CFR 75.205(a)), and other
sources of historical information. These systems include, but are not limited to: FAPIIS
(https://www.fapiis.gov/), including past performance on federal contracts as per Duncan Hunter
National Defense Authorization Act of 2009; Do Not Pay list; and System for Award
Management (SAM) exclusions.
CDC requires all applicants to complete the Risk Questionnaire, OMB Control Number 0920Page 33 of 61
1132 annually. This questionnaire, which is located
at https://www.cdc.gov/grants/documents/PPMR-G-CDC-Risk-Questionnaire.pdf, along with
supporting documentation must be submitted with your application by the closing date of the
Notice of Funding Opportunity Announcement. If your organization has completed CDC’s Risk
Questionnaire within the past 12 months of the closing date of this NOFO, then you must submit
a copy of that questionnaire, or submit a letter signed by the authorized organization
representative to include the original submission date, organization’s EIN and UEI.
When uploading supporting documentation for the Risk Questionnaire into this application
package, clearly label the documents for easy identification of the type of documentation. For
example, a copy of Procurement policy submitted in response to the questionnaire may be
labeled using the following format: Risk Questionnaire Supporting Documents _ Procurement
Policy.
Duplication of Efforts
Applicants are responsible for reporting if this application will result in programmatic,
budgetary, or commitment overlap with another application or award (i.e. grant, cooperative
agreement, or contract) submitted to another funding source in the same fiscal
year. Programmatic overlap occurs when (1) substantially the same project is proposed in more
than one application or is submitted to two or more funding sources for review and funding
consideration or (2) a specific objective and the project design for accomplishing the objective
are the same or closely related in two or more applications or awards, regardless of the funding
source. Budgetary overlap occurs when duplicate or equivalent budgetary items (e.g.,
equipment, salaries) are requested in an application but already are provided by another
source. Commitment overlap occurs when an individual’s time commitment exceeds 100
percent, whether or not salary support is requested in the application. Overlap, whether
programmatic, budgetary, or commitment of an individual’s effort greater than 100 percent, is
not permitted. Any overlap will be resolved by the CDC with the applicant and the PD/PI prior
to award.
Report Submission: The applicant must upload the report in Grants.gov under “Other
Attachment Forms.” The document should be labeled: "Report on Programmatic, Budgetary,
and Commitment Overlap.”
6. Content and Form of Application Submission
Applicants are required to include all of the following documents with their application package
at www.grants.gov.
7. Letter of Intent
A Letter of Intent (LOI) is requested, not required. The purpose of an LOI is to allow CDC
program staff to estimate the number of and plan for the review of submitted applications. LOI
should be submitted by the lead applicant or lead fiduciary agent and simply indicate the intent
to submit an application, along with a listing of identified partner organizations.
LOI must be sent via email to:
Page 34 of 61
Rebekah Buckley
CDC, NCCDPHP
InnovativeCVH@cdc.gov
8. Table of Contents
(There is no page limit. The table of contents is not included in the project narrative page
limit.): The applicant must provide, as a separate attachment, the “Table of Contents” for the
entire submission package.
Provide a detailed table of contents for the entire submission package that includes all of the
documents in the application and headings in the "Project Narrative" section. Name the file
"Table of Contents" and upload it as a PDF file under "Other Attachment Forms"
at www.grants.gov.
9. Project Abstract Summary
A project abstract is included on the mandatory documents list and must be submitted
at www.grants.gov. The project abstract must be a self-contained, brief summary of the proposed
project including the purpose and outcomes. This summary must not include any proprietary or
confidential information. Applicants must enter the summary in the "Project Abstract Summary"
text box at www.grants.gov.
10. Project Narrative
(Unless specified in the "H. Other Information" section, maximum of 20 pages, single spaced, 12
point font, 1-inch margins, number all pages. This includes the work plan. Content beyond the
specified page number will not be reviewed.)
Applicants must submit a Project Narrative with the application forms. Applicants must name
this file “Project Narrative” and upload it at www.grants.gov. The Project Narrative must
include all of the following headings (including subheadings): Background, Approach,
Applicant Evaluation and Performance Measurement Plan, Organizational Capacity of
Applicants to Implement the Approach, and Work Plan. The Project Narrative must be succinct,
self-explanatory, and in the order outlined in this section. It must address outcomes and activities
to be conducted over the entire period of performance as identified in the CDC Project
Description section. Applicants should use the federal plain language guidelines and Clear
Communication Index to respond to this Notice of Funding Opportunity. Note that recipients
should also use these tools when creating public communication materials supported by this
NOFO. Failure to follow the guidance and format may negatively impact scoring of the
application.
a. Background
Applicants must provide a description of relevant background information that includes the
context of the problem (See CDC Background).
b. Approach
i. Purpose
Page 35 of 61
Applicants must describe in 2-3 sentences specifically how their application will address the
public health problem as described in the CDC Background section.
ii. Outcomes
Applicants must clearly identify the outcomes they expect to achieve by the end of the project
period, as identified in the logic model in the Approach section of the CDC Project Description.
Outcomes are the results that the program intends to achieve and usually indicate the intended
direction of change (e.g., increase, decrease).
iii. Strategies and Activities
Applicants must provide a clear and concise description of the strategies and activities they will
use to achieve the period of performance outcomes. Applicants must select existing evidencebased strategies that meet their needs, or describe in the Applicant Evaluation and Performance
Measurement Plan how these strategies will be evaluated over the course of the project period.
See the Strategies and Activities section of the CDC Project Description.
1. Collaborations
Applicants must describe how they will collaborate with programs and organizations either
internal or external to CDC. Applicants must address the Collaboration requirements as
described in the CDC Project Description.
2. Target Populations and Health Disparities
Applicants must describe the specific target population(s) in their jurisdiction and explain how
such a target will achieve the goals of the award and/or alleviate health disparities. The
applicants must also address how they will include specific populations that can benefit from the
program that is described in the Approach section. Applicants must address the Target
Populations and Health Disparities requirements as described in the CDC Project Description.
c. Applicant Evaluation and Performance Measurement Plan
Applicants must provide an evaluation and performance measurement plan that demonstrates
how the recipient will fulfill the requirements described in the CDC Evaluation and Performance
Measurement and Project Description sections of this NOFO. At a minimum, the plan must
describe:
How applicant will collect the performance measures, respond to the evaluation
questions, and use evaluation findings for continuous program quality improvement. The
Paperwork Reduction Act of 1995 (PRA): Applicants are advised that any activities
involving information collections (e.g., surveys, questionnaires, applications, audits, data
requests, reporting, recordkeeping and disclosure requirements) from 10 or more
individuals or non-Federal entities, including State and local governmental agencies, and
funded or sponsored by the Federal Government are subject to review and approval by
the Office of Management and Budget. For further information about CDC’s
requirements under PRA see http://www.hhs.gov/ ocio/policy/collection/.
Page 36 of 61
How key program partners will participate in the evaluation and performance
measurement planning processes.
Available data sources, feasibility of collecting appropriate evaluation and performance
data, data management plan (DMP), and other relevant data information (e.g.,
performance measures proposed by the applicant).
Where the applicant chooses to, or is expected to, take on specific evaluation studies, they should
be directed to:
Describe the type of evaluations (i.e., process, outcome, or both).
Describe key evaluation questions to be addressed by these evaluations.
Describe other information (e.g., measures, data sources).
Recipients will be required to submit a more detailed Evaluation and Performance Measurement
plan (including the DMP elements) within the first 6 months of award, as described in the
Reporting Section of this NOFO.
d. Organizational Capacity of Applicants to Implement the Approach
Applicants must address the organizational capacity requirements as described in the CDC
Project Description.
11. Work Plan
(Included in the Project Narrative’s page limit)
Applicants must prepare a work plan consistent with the CDC Project Description Work Plan
section. The work plan integrates and delineates more specifically how the recipient plans to
carry out achieving the period of performance outcomes, strategies and activities, evaluation and
performance measurement.
12. Budget Narrative
Applicants must submit an itemized budget narrative. When developing the budget narrative,
applicants must consider whether the proposed budget is reasonable and consistent with the
purpose, outcomes, and program strategy outlined in the project narrative. The budget must
include:
Salaries and wages
Fringe benefits
Consultant costs
Equipment
Supplies
Travel
Other categories
Page 37 of 61
Contractual costs
Total Direct costs
Total Indirect costs
Indirect costs could include the cost of collecting, managing, sharing and preserving data.
Indirect costs on grants awarded to foreign organizations and foreign public entities and
performed fully outside of the territorial limits of the U.S. may be paid to support the costs of
compliance with federal requirements at a fixed rate of eight percent of MTDC exclusive of
tuition and related fees, direct expenditures for equipment, and subawards in excess of
$25,000. Negotiated indirect costs may be paid to the American University, Beirut, and the
World Health Organization.
If applicable and consistent with the cited statutory authority for this announcement, applicant
entities may use funds for activities as they relate to the intent of this NOFO to meet national
standards or seek health department accreditation through the Public Health Accreditation Board
(see: http://www.phaboard.org). Applicant entities to whom this provision applies include state,
local, territorial governments (including the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American
Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the
Republic of Palau), or their bona fide agents, political subdivisions of states (in consultation with
states), federally recognized or state-recognized American Indian or Alaska Native tribal
governments, and American Indian or Alaska Native tribally designated organizations. Activities
include those that enable a public health organization to deliver public health services such as
activities that ensure a capable and qualified workforce, up-to-date information systems, and the
capability to assess and respond to public health needs. Use of these funds must focus on
achieving a minimum of one national standard that supports the intent of the NOFO. Proposed
activities must be included in the budget narrative and must indicate which standards will be
addressed.
Vital records data, including births and deaths, are used to inform public health program and
policy decisions. If applicable and consistent with the cited statutory authority for this NOFO,
applicant entities are encouraged to collaborate with and support their jurisdiction’s vital records
office (VRO) to improve vital records data timeliness, quality and access, and to advance public
health goals. Recipients may, for example, use funds to support efforts to build VRO capacity
through partnerships; provide technical and/or financial assistance to improve vital records
timeliness, quality or access; or support vital records improvement efforts, as approved by CDC.
Applicants must name this file “Budget Narrative” and upload it as a PDF file
at www.grants.gov. If requesting indirect costs in the budget, a copy of the indirect cost-rate
agreement is required. If the indirect costs are requested, include a copy of the current negotiated
federal indirect cost rate agreement or a cost allocation plan approval letter for those Recipients
under such a plan. Applicants must name this file “Indirect Cost Rate” and upload it
at www.grants.gov.
Recipients are required to work with professional evaluators (either internal or external) to meet
the evaluation and performance reporting requirements of this NOFO. Therefore, CDC strongly
Page 38 of 61
recommends allocating at least 15% of the total funding award to evaluation and performance
monitoring and to consider both development and implementation costs.
13. Funds Tracking
Proper fiscal oversight is critical to maintaining public trust in the stewardship of federal funds.
Effective October 1, 2013, a new HHS policy on subaccounts requires the CDC to set up
payment subaccounts within the Payment Management System (PMS) for all new grant awards.
Funds awarded in support of approved activities and drawdown instructions will be identified on
the Notice of Award in a newly established PMS subaccount (P subaccount). Recipients will be
required to draw down funds from award-specific accounts in the PMS. Ultimately, the
subaccounts will provide recipients and CDC a more detailed and precise understanding of
financial transactions. The successful applicant will be required to track funds by P-accounts/sub
accounts for each project/cooperative agreement awarded. Applicants are encouraged to
demonstrate a record of fiscal responsibility and the ability to provide sufficient and effective
oversight. Financial management systems must meet the requirements as described 45 CFR 75
which include, but are not limited to, the following:
Records that identify adequately the source and application of funds for federally-funded
activities.
Effective control over, and accountability for, all funds, property, and other assets.
Comparison of expenditures with budget amounts for each Federal award.
Written procedures to implement payment requirements.
Written procedures for determining cost allowability.
Written procedures for financial reporting and monitoring.
14. Pilot Program for Enhancement of Employee Whistleblower Protections
Pilot Program for Enhancement of Employee Whistleblower Protections: All applicants will be
subject to a term and condition that applies the terms of 48 Code of Federal Regulations
(CFR) section 3.908 to the award and requires that recipients inform their employees in writing
(in the predominant native language of the workforce) of employee whistleblower rights and
protections under 41 U.S.C. 4712.
15. Copyright Interests Provisions
This provision is intended to ensure that the public has access to the results and accomplishments
of public health activities funded by CDC. Pursuant to applicable grant regulations and CDC’s
Public Access Policy, Recipient agrees to submit into the National Institutes of Health (NIH)
Manuscript Submission (NIHMS) system an electronic version of the final, peer-reviewed
manuscript of any such work developed under this award upon acceptance for publication, to be
made publicly available no later than 12 months after the official date of publication. Also at the
time of submission, Recipient and/or the Recipient’s submitting author must specify the date the
final manuscript will be publicly accessible through PubMed Central (PMC). Recipient and/or
Recipient’s submitting author must also post the manuscript through PMC within twelve (12)
Page 39 of 61
months of the publisher's official date of final publication; however the author is strongly
encouraged to make the subject manuscript available as soon as possible. The recipient must
obtain prior approval from the CDC for any exception to this provision.
The author's final, peer-reviewed manuscript is defined as the final version accepted for journal
publication, and includes all modifications from the publishing peer review process, and all
graphics and supplemental material associated with the article. Recipient and its submitting
authors working under this award are responsible for ensuring that any publishing or copyright
agreements concerning submitted articles reserve adequate right to fully comply with this
provision and the license reserved by CDC. The manuscript will be hosted in both PMC and the
CDC Stacks institutional repository system. In progress reports for this award, recipient must
identify publications subject to the CDC Public Access Policy by using the applicable NIHMS
identification number for up to three (3) months after the publication date and the PubMed
Central identification number (PMCID) thereafter.
16. Funding Restrictions
Restrictions that must be considered while planning the programs and writing the budget are:
Recipients may not use funds for research.
Recipients may not use funds for clinical care except as allowed by law.
Recipients may use funds only for reasonable program purposes, including personnel,
travel, supplies, and services.
Generally, recipients may not use funds to purchase furniture or equipment. Any such
proposed spending must be clearly identified in the budget.
Reimbursement of pre-award costs generally is not allowed, unless the CDC provides
written approval to the recipient.
Other than for normal and recognized executive-legislative relationships, no funds may
be used for:
o publicity or propaganda purposes, for the preparation, distribution, or use of any
material designed to support or defeat the enactment of legislation before any
legislative body
o the salary or expenses of any grant or contract recipient, or agent acting for such
recipient, related to any activity designed to influence the enactment of
legislation, appropriations, regulation, administrative action, or Executive order
proposed or pending before any legislative body
See Additional Requirement (AR) 12 for detailed guidance on this prohibition
and additional guidance on lobbying for CDC recipients.
The direct and primary recipient in a cooperative agreement program must perform a
substantial role in carrying out project outcomes and not merely serve as a conduit for an
award to another party or provider who is ineligible.
Page 40 of 61
17. Data Management Plan
As identified in the Evaluation and Performance Measurement section, applications involving
data collection or generation must include a Data Management Plan (DMP) as part of their
evaluation and performance measurement plan unless CDC has stated that CDC will take on the
responsibility of creating the DMP. The DMP describes plans for assurance of the quality of the
public health data through the data's lifecycle and plans to deposit the data in a repository to
preserve and to make the data accessible in a timely manner. See web link for additional
information:
https://www.cdc.gov/grants/additional-requirements/ar-25.html.
18. Other Submission Requirements
a. Electronic Submission:
Applications must be submitted electronically by using the forms and instructions posted for this
notice of funding opportunity at www.grants.gov. Applicants can complete the application
package using Workspace, which allows forms to be filled out online or offline. All application
attachments must be submitted using a PDF file format. Instructions and training for using
Workspace can be found at www.grants.gov under the "Workspace Overview" option.
b. Tracking Number: Applications submitted through www.grants.gov are time/date stamped
electronically and assigned a tracking number. The applicant’s Authorized Organization
Representative (AOR) will be sent an e-mail notice of receipt when www.grants.gov receives the
application. The tracking number documents that the application has been submitted and initiates
the required electronic validation process before the application is made available to CDC.
c. Validation Process: Application submission is not concluded until the validation process is
completed successfully. After the application package is submitted, the applicant will receive a
“submission receipt” e-mail generated by www.grants.gov. A second e-mail message to
applicants will then be generated by www.grants.gov that will either validate or reject the
submitted application package. This validation process may take as long as two business days.
Applicants are strongly encouraged to check the status of their application to ensure that
submission of their package has been completed and no submission errors have occurred.
Applicants also are strongly encouraged to allocate ample time for filing to guarantee that their
application can be submitted and validated by the deadline published in the NOFO. Nonvalidated applications will not be accepted after the published application deadline date.
If you do not receive a “validation” e-mail within two business days of application submission,
please contact www.grants.gov. For instructions on how to track your application, refer to the email message generated at the time of application submission or the Grants.gov Online User
Guide.
https:// www.grants.gov/help/html/help/index.htm? callingApp=custom#t=
Get_Started%2FGet_Started. htm
d. Technical Difficulties: If technical difficulties are encountered at www.grants.gov, applicants
should contact Customer Service at www.grants.gov. The www.grants.gov Contact Center is
available 24 hours a day, 7 days a week, except federal holidays. The Contact Center is available
Page 41 of 61
by phone at 1-800-518-4726 or by e-mail at support@grants.gov. Application submissions sent
by e-mail or fax, or on CDs or thumb drives will not be accepted. Please note that
www.grants.gov is managed by HHS.
e. Paper Submission: If technical difficulties are encountered at www.grants.gov, applicants
should call the www.grants.gov Contact Center at 1-800-518-4726 or e-mail them
at support@grants.gov for assistance. After consulting with the Contact Center, if the technical
difficulties remain unresolved and electronic submission is not possible, applicants may e-mail
CDC GMO/GMS, before the deadline, and request permission to submit a paper application.
Such requests are handled on a case-by-case basis.
An applicant’s request for permission to submit a paper application must:
1. Include the www.grants.gov case number assigned to the inquiry
2. Describe the difficulties that prevent electronic submission and the efforts taken with
the www.grants.gov Contact Center to submit electronically; and
3. Be received via e-mail to the GMS/GMO listed below at least three calendar days before
the application deadline. Paper applications submitted without prior approval will not be
considered.
If a paper application is authorized, OGS will advise the applicant of specific instructions
for submitting the application via email.
E. Review and Selection Process
1. Review and Selection Process: Applications will be reviewed in three phases
a. Phase 1 Review
All applications will be initially reviewed for eligibility and completeness by CDC Office of
Grants Services. Complete applications will be reviewed for responsiveness by the Grants
Management Officials and Program Officials. Non-responsive applications will not advance to
Phase II review. Applicants will be notified that their applications did not meet eligibility and/or
published submission requirements.
b. Phase II Review
A review panel will evaluate complete, eligible applications in accordance with the criteria
below.
i. Approach
ii. Evaluation and Performance Measurement
iii. Applicant’s Organizational Capacity to Implement the Approach
Not more than thirty days after the Phase II review is completed, applicants will be notified
electronically if their application does not meet eligibility or published submission requirements
i. Approach
Maximum Points: 35
Page 42 of 61
Overall Program Strategy (12 points total)
The extent to which an applicant describes:
Establishing, or aligning with and joining an existing, learning collaborative (LC) that
serves as a hub of entities focused on developing innovative approaches to improve
overall cardiovascular (CVD) health. The LC must be equipped to apply those
approaches to mitigate social service and support needs and other associated risk factors
for CVD within approved populations of focus.
An approach to using Geographic Information System (GIS), or other Geo-mapping
technology that highlights census geographies to identify approvable populations of focus
identified for this NOFO as adults aged 18 and older with a hypertension crude
prevalence of 53% or higher, as shown by data specifically at the census tract level.
An approach to working through partners to increase the percentage of adults within
approved populations of focus, 18–85 years of age who have had a hypertension
diagnosis and among those diagnosed have had their blood pressure adequately
controlled during the measurement year.
Strategy 1. Track and Monitor Clinical Measures shown to improve health and wellness, and
health care quality within approved populations of focus and identify patients with hypertension
and high cholesterol. (6 points)
The extent to which an applicant describes how they will:
Advance the adoption and use of EHRs and HIT to identify, track, and monitor clinical
and social support needs measures to address health care disparities and health outcomes
within approved populations of focus.
Promote the use of standardized processes or tools, such as GIS or other Geo-mapping
tools, to identify the social services and support needs within approved populations of
focus, and monitor and assess the referral and utilization of those services, such as the
need for transportation, housing, childcare, etc.
Strategy 2. Implement Team-Based Care to prevent, detect, control and manage hypertension
and high cholesterol within approved populations of focus. (6 points)
The extent to which an applicant describes how they will:
Advance the use of health information systems that support team-based care to monitor
and address hypertension and high cholesterol within approved populations of focus.
Assemble or create multidisciplinary teams to identify social services and support needs
within approved populations of focus.
Build and manage a coordinated network of multidisciplinary partnerships that address
identified barriers and needs within approved populations of focus, related to their social
services and support needs (e.g., childcare, transportation, language translation, food
assistance, and housing).
Strategy 3. Link Community Resources and Clinical Services that support comprehensive
bidirectional referral and follow-up systems aimed at mitigating social services and support
barriers for optimal health outcomes within approved populations of focus. (6 points)
The extent to which an applicant describes how they will:
Page 43 of 61
Create and enhance community-clinical links to identify social determinants of health
{(SDOH) e.g., housing, transportation, access to care, and community resources} and
respond to the individual social services and support needs within approved populations
of focus.
Identify and deploy dedicated CHWs (or their equivalents) to provide a continuum of
care and services which extend the benefits of clinical interventions and address social
services and support needs leading to optimal health outcomes within approved
populations of focus.
Promote the use of self-measured blood pressure monitoring with clinical support within
approved populations of focus.
Work Plan (5 Points total)
The extent to which an applicant:
Provides a detailed work plan for the first year of the award and describes the activities
and timelines that will support the achievement of the outcomes. Activities must align
with the logic model and have appropriate performance measures or milestones for
accomplishing tasks. A timeline, evaluation, data collection activities, and staff person
responsible for oversight must be included.
ii. Evaluation and Performance Measurement
The extent to which an applicant:
Maximum Points: 30
Describes specific evaluation questions, in addition to the broad evaluation questions
posed by CDC, that their proposed evaluation will answer and that are aligned with the
purpose of this Cooperative Agreement to improve hypertension control within approved
populations of focus.
Describes an evaluation design that is rigorous enough to clearly document the
innovative approaches to the proposed strategies and the contribution of the strategies to
outcomes outlined in the logic model. This design should include a clear description of
indicators, data sources, data collection methods, analysis plans, and dissemination
activities.
Clearly describes their access to performance measure data (e.g., hypertension control
within approved populations of focus) and how they will meet the requirements to report
performance measure data to CDC semiannually.
Clearly demonstrates how and how much of the total funding is allocated to evaluation
and performance measurement. This should be explicitly described in the Evaluation and
Performance Measurement section and documented in the staffing plans and budget.
Includes a preliminary Data Management Plan (DMP).
iii. Applicant's Organizational Capacity to Implement the
Approach
Organizational Capacity (25 points total)
Maximum Points: 35
The extent to which an applicant:
Page 44 of 61
Describes how they will coordinate efforts with other publicly and privately funded
programs within the state to leverage resources and maximize reach and impact to
address SDOH and social services and support needs related to CVD within approved
populations of focus.
Describes their capacity to manage programs and resources ensuring the administrative,
financial, and staff support necessary to sustain activities. This includes describing an
adequate staffing plan, providing CVs or resumes for proposed personnel, a description
of how program performance will be monitored and how the program will be adjusted to
address identified challenges, an organizational chart, and a project management
structure that clearly defines staff roles and reporting structure as it applies to this
funding opportunity.
Describes a dedicated staff explicitly included in the work plan and budget, who will
focus on health inequities and build relationships at the designated levels to decrease
health care disparities and advance health equity.
Describes their previous experience working with organizations to implement
interventions within approved populations of focus.
Describes their proposed program plan that demonstrates the ability to document and
disseminate evaluation findings, outcomes, and recommendations, including the
outcomes and achievements resulting from collaborative work with partners.
Collaborations (10 points total)
The extent to which an applicant:
Describes how they will collaborate with CDC-funded programs and health equity
subject-matter experts.
Describes how they will establish or partner with multi-sectorial learning collaboratives
(LC) and collaborate with organizations with a history of working within approved
populations of focus.
Provides letters of support or Memorandums of Agreement from proposed LC partners.
Budget
The extent to which an applicant:
Maximum Points: 0
Describes how the budget supports the work plan and evaluation plan.
Provides an accurate and reasonable budget.
Describes how and how much of the total funding is allocated to evaluation and
performance measurement.
c. Phase III Review
Applications will be reviewed and scored in accordance with the Phase II review criteria. The
CDC will provide funding to up to 12 applicants.
Page 45 of 61
Applications may be funded out of rank order to ensure geographic representation across the
U.S. to ensure the greatest reach for priority populations. The CDC will provide justification for
any application funded out of rank order.
Review of risk posed by applicants.
Prior to making a Federal award, CDC is required by 31 U.S.C. 3321 and 41 U.S.C. 2313 to
review information available through any OMB-designated repositories of government-wide
eligibility qualification or financial integrity information as appropriate. See also suspension and
debarment requirements at 2 CFR parts 180 and 376.
In accordance 41 U.S.C. 2313, CDC is required to review the non-public segment of the OMBdesignated integrity and performance system accessible through SAM (currently the
Federal Recipient Performance and Integrity Information System (FAPIIS)) prior to making a
Federal award where the Federal share is expected to exceed the simplified acquisition threshold,
defined in 41 U.S.C. 134, over the period of performance. At a minimum, the information in the
system for a prior Federal award recipient must demonstrate a satisfactory record of executing
programs or activities under Federal grants, cooperative agreements, or procurement awards; and
integrity and business ethics. CDC may make a Federal award to a recipient who does not fully
meet these standards, if it is determined that the information is not relevant to the current Federal
award under consideration or there are specific conditions that can appropriately mitigate the
effects of the non-Federal entity's risk in accordance with 45 CFR §75.207.
CDC’s framework for evaluating the risks posed by an applicant may incorporate results of the
evaluation of the applicant's eligibility or the quality of its application. If it is determined that a
Federal award will be made, special conditions that correspond to the degree of risk assessed
may be applied to the Federal award. The evaluation criteria is described in this Notice of
Funding Opportunity.
In evaluating risks posed by applicants, CDC will use a risk-based approach and may consider
any items such as the following:
(1) Financial stability;
(2) Quality of management systems and ability to meet the management standards prescribed in
this part;
(3) History of performance. The applicant's record in managing Federal awards, if it is a prior
recipient of Federal awards, including timeliness of compliance with applicable reporting
requirements, conformance to the terms and conditions of previous Federal awards, and if
applicable, the extent to which any previously awarded amounts will be expended prior to future
awards;
(4) Reports and findings from audits performed under subpart F 45 CFR 75 or the reports and
findings of any other available audits; and
(5) The applicant's ability to effectively implement statutory, regulatory, or other requirements
imposed on non-Federal entities.
CDC must comply with the guidelines on government-wide suspension and debarment in 2 CFR
part 180, and require non-Federal entities to comply with these provisions. These provisions
Page 46 of 61
restrict Federal awards, subawards and contracts with certain parties that are debarred, suspended
or otherwise excluded from or ineligible for participation in Federal programs or activities.
2. Announcement and Anticipated Award Dates
Successful applicants can anticipate notice of funding by August 30, 2023, with a start date of
September 30, 2023.
F. Award Administration Information
1. Award Notices
Recipients will receive an electronic copy of the Notice of Award (NOA) from CDC OGS. The
NOA shall be the only binding, authorizing document between the recipient and CDC. The
NOA will be signed by an authorized GMO and emailed to the Recipient Business Officer listed
in application and the Program Director.
Any applicant awarded funds in response to this Notice of Funding Opportunity will be subject
to annual SAM Registration and Federal Funding Accountability And Transparency Act Of 2006
(FFATA) requirements.
Unsuccessful applicants will receive notification of these results by e-mail with delivery receipt.
2. Administrative and National Policy Requirements
Recipients must comply with the administrative and public policy requirements outlined in 45
CFR Part 75 and the HHS Grants Policy Statement, as appropriate.
Brief descriptions of relevant provisions are available at https://www.cdc.gov/grants/additionalrequirements/index.html.
The HHS Grants Policy Statement is available
at http://www.hhs.gov/sites/default/files/grants/grants/policies-regulations/hhsgps107.pdf.
AR-1: Human Subjects Requirements
AR-2: Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research
AR-3: Animal Subjects Requirements
AR-9: Paperwork Reduction Act Requirements
AR-10: Smoke-Free Workplace Requirements
AR-11: Healthy People 2030
AR-12: Lobbying Restrictions
AR-13: Prohibition on Use of CDC Funds for Certain Gun Control Activities
AR-14: Accounting System Requirements
AR-16: Security Clearance Requirement
AR-17: Peer and Technical Reviews of Final Reports of Health Studies – ATSDR
Page 47 of 61
AR-21: Small, Minority, And Women-owned Business
AR-22: Research Integrity
AR-24: Health Insurance Portability and Accountability Act Requirements
AR-25: Data Management and Access
AR-26: National Historic Preservation Act of 1966
AR-28: Inclusion of Persons Under the Age of 21 in Research
AR-29: Compliance with EO13513, “Federal Leadership on Reducing Text Messaging while
Driving”, October 1, 2009
AR-30: Information Letter 10-006, - Compliance with Section 508 of the Rehabilitation Act of
1973
AR-31: Research Definition
AR-32: Appropriations Act, General Provisions
AR-33: United States Government Policy for Institutional Oversight of Life Sciences Dual Use
Research of Concern
AR-37: Prohibition on certain telecommunications and video surveillance services or equipment
for all awards issued on or after August 13, 2020
The full text of the Uniform Administrative Requirements, Cost Principles, and Audit
Requirements for HHS Awards, 45 CFR 75, can be found at: https://www.ecfr.gov/cgi-bin/textidx?node=pt45.1.75
Should you successfully compete for an award, recipients of federal financial assistance (FFA)
from HHS will be required to complete an HHS Assurance of Compliance form (HHS 690) in
which you agree, as a condition of receiving the grant, to administer your programs in
compliance with federal civil rights laws that prohibit discrimination on the basis of race, color,
national origin, age, sex and disability, and agreeing to comply with federal conscience laws,
where applicable. This includes ensuring that entities take meaningful steps to provide
meaningful access to persons with limited English proficiency; and ensuring effective
communication with persons with disabilities. Where applicable, Title XI and Section 1557
prohibit discrimination on the basis of sexual orientation, and gender identity. The HHS Office
for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See
https://www.hhs.gov/civil-rights/for-providers/provider- obligations/index.html and
https://www.hhs.gov/civil-rights/for- individuals/nondiscrimination/index.html.
For guidance on meeting your legal obligation to take reasonable steps to ensure
meaningful access to your programs or activities by limited English proficient
individuals, see https://www.hhs.gov/civil-rights/for-individuals/special-topics/limitedenglish-proficiency/fact-sheet-guidance/index.html and https://www.lep.gov.
For information on your specific legal obligations for serving qualified individuals with
disabilities, including providing program access, reasonable modifications, and to provide
Page 48 of 61
effective communication, see
http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html.
HHS funded health and education programs must be administered in an environment free
of sexual harassment, see https://www.hhs.gov/civil-rights/for-individuals/sexdiscrimination/index.html.
For guidance on administering your project in compliance with applicable federal
religious nondiscrimination laws and applicable federal conscience protection and
associated anti-discrimination laws, see https://www.hhs.gov/conscience/conscienceprotections/index.html and https://www.hhs.gov/conscience/religiousfreedom/index.html.
3. Reporting
Reporting provides continuous program monitoring and identifies successes and challenges
that recipients encounter throughout the project period. Also, reporting is a requirement
for recipients who want to apply for yearly continuation of funding. Reporting helps CDC and
recipients because it:
Helps target support to recipients;
Provides CDC with periodic data to monitor recipient progress toward meeting the Notice
of Funding Opportunity outcomes and overall performance;
Allows CDC to track performance measures and evaluation findings for continuous
quality and program improvement throughout the period of performance and to determine
applicability of evidence-based approaches to different populations, settings, and
contexts; and
Enables CDC to assess the overall effectiveness and influence of the NOFO.
The table below summarizes required and optional reports. All required reports must be sent
electronically to GMS listed in the “Agency Contacts” section of the NOFO copying the CDC
Project Officer.
Report
Recipient Evaluation and
Performance Measurement
Plan, including Data
Management Plan (DMP)
Annual Performance Report
(APR)
When?
6 months into award
Required?
Yes
No later than 120 days before
Yes
end of budget period. Serves as
yearly continuation application.
Data on Performance Measures. Reporting is required on a semi- Yes
annual basis.
Federal Financial Reporting
90 days after the end of the budget Yes
Forms
period
Final Performance and
90 days after end of period of
Yes
Financial Report
performance
Page 49 of 61
Recipients are required to report all performance measures more frequently than annually in the
APR. Semi-annual reporting is required for all performance measures. Specific dates of
reporting, data fields, and format will be provided at the beginning of the award period.
a. Recipient Evaluation and Performance Measurement Plan (required)
With support from CDC, recipients must elaborate on their initial applicant evaluation and
performance measurement plan. This plan must be no more than 20 pages; recipients must
submit the plan 6 months into the award. HHS/CDC will review and approve the recipient’s
monitoring and evaluation plan to ensure that it is appropriate for the activities to be undertaken
as part of the agreement, for compliance with the monitoring and evaluation guidance established
by HHS/CDC, or other guidance otherwise applicable to this Agreement.
Recipient Evaluation and Performance Measurement Plan (required): This plan should provide
additional detail on the following:
Performance Measurement
• Performance measures and targets
• The frequency that performance data are to be collected.
• How performance data will be reported.
• How quality of performance data will be assured.
• How performance measurement will yield findings to demonstrate progress towards
achieving NOFO goals (e.g., reaching target populations or achieving expected outcomes).
• Dissemination channels and audiences.
• Other information requested as determined by the CDC program.
Evaluation
• The types of evaluations to be conducted (e.g. process or outcome evaluations).
• The frequency that evaluations will be conducted.
• How evaluation reports will be published on a publicly available website.
• How evaluation findings will be used to ensure continuous quality and program improvement.
• How evaluation will yield findings to demonstrate the value of the NOFO (e.g., effect on
improving public health outcomes, effectiveness of NOFO, cost-effectiveness or cost-benefit).
• Dissemination channels and audiences.
HHS/CDC or its designee will also undertake monitoring and evaluation of the defined activities
within the agreement. The recipient must ensure reasonable access by HHS/CDC or its designee
to all necessary sites, documentation, individuals and information to monitor, evaluate and verify
the appropriate implementation the activities and use of HHS/CDC funding under this
Agreement.
Page 50 of 61
b. Annual Performance Report (APR) (required)
The recipient must submit the APR via www.Grantsolutions.gov no later than 120 days prior to
the end of the budget period. This report must not exceed 45 pages excluding administrative
reporting. Attachments are not allowed, but web links are allowed.
This report must include the following:
Performance Measures: Recipients must report on performance measures for each
budget period and update measures, if needed.
Evaluation Results: Recipients must report evaluation results for the work completed to
date (including findings from process or outcome evaluations).
Work Plan: Recipients must update work plan each budget period to reflect any changes
in period of performance outcomes, activities, timeline, etc.
Successes
o Recipients must report progress on completing activities and progress towards
achieving the period of performance outcomes described in the logic model and
work plan.
o Recipients must describe any additional successes (e.g. identified through
evaluation results or lessons learned) achieved in the past year.
o Recipients must describe success stories.
Challenges
o Recipients must describe any challenges that hindered or might hinder their
ability to complete the work plan activities and achieve the period of performance
outcomes.
o Recipients must describe any additional challenges (e.g., identified through
evaluation results or lessons learned) encountered in the past year.
CDC Program Support to Recipients
o Recipients must describe how CDC could help them overcome challenges to
complete activities in the work plan and achieving period of performance
outcomes.
Administrative Reporting (No page limit)
o SF-424A Budget Information-Non-Construction Programs.
o Budget Narrative – Must use the format outlined in "Content and Form of
Application Submission, Budget Narrative" section.
o Indirect Cost Rate Agreement.
The recipients must submit the Annual Performance Report via www.Grantsolutions.gov no
later than 120 days prior to the end of the budget period.
c. Performance Measure Reporting (optional)
Page 51 of 61
CDC programs may require more frequent reporting of performance measures than annually in
the APR. If this is the case, CDC programs must specify reporting frequency, data fields, and
format for recipients at the beginning of the award period.
Recipients are required to report all performance measures more frequently than annually in the
APR. Semi-annual reporting is required for all performance measures. Specific dates of
reporting, data fields, and format will be provided at the beginning of the award period.
d. Federal Financial Reporting (FFR) (required)
The annual FFR form (SF-425) is required and must be submitted 90 days after the end of the
budget period through the Payment Management System (PMS). The report must include only
those funds authorized and disbursed during the timeframe covered by the report. The final FFR
must indicate the exact balance of unobligated funds, and may not reflect any unliquidated
obligations. There must be no discrepancies between the final FFR expenditure data and the
Payment Management System’s (PMS) cash transaction data. Failure to submit the required
information by the due date may adversely affect the future funding of the project. If the
information cannot be provided by the due date, recipients are required to submit a letter of
explanation to OGS and include the date by which the Grants Officer will receive information.
e. Final Performance and Financial Report (required)
The Final Performance Report is due 90 days after the end of the period of performance. The
Final FFR is due 90 days after the end of the period of performance and must be submitted
through the Payment Management System (PMS). CDC programs must indicate that this report
should not exceed 40 pages. This report covers the entire period of performance and can include
information previously reported in APRs. At a minimum, this report must include the following:
Performance Measures – Recipients must report final performance data for all process
and outcome performance measures.
Evaluation Results – Recipients must report final evaluation results for the period of
performance for any evaluations conducted.
Impact/Results/Success Stories – Recipients must use their performance measure results
and their evaluation findings to describe the effects or results of the work completed over
the project period, and can include some success stories.
A final Data Management Plan that includes the location of the data collected during the
funded period, for example, repository name and link data set(s)
Additional forms as described in the Notice of Award (e.g., Equipment Inventory Report,
Final Invention Statement).
4. Federal Funding Accountability and Transparency Act of 2006 (FFATA)
Federal Funding Accountability and Transparency Act of 2006 (FFATA), P.L. 109–282, as
amended by section 6202 of P.L. 110–252 requires full disclosure of all entities and
organizations receiving Federal funds including awards, contracts, loans, other assistance, and
payments through a single publicly accessible Web site, http://www.USASpending.gov.
Compliance with this law is primarily the responsibility of the Federal agency. However, two
elements of the law require information to be collected and reported by applicants: 1)
Page 52 of 61
information on executive compensation when not already reported through the SAM, and 2)
similar information on all sub-awards/subcontracts/consortiums over $25,000.
For the full text of the requirements under the FFATA and HHS guidelines, go to:
https://www.gpo.gov/fdsys/pkg/PLAW-109publ282/pdf/PLAW-109publ282.pdf,
https://www. fsrs.gov/documents /ffata_legislation_ 110_252.pdf
http://www.hhs.gov/grants/grants/grants-policies-regulations/index.html#FFATA.
5. Reporting of Foreign Taxes (International/Foreign projects only)
A. Valued Added Tax (VAT) and Customs Duties – Customs and import duties, consular fees,
customs surtax, valued added taxes, and other related charges are hereby authorized as an
allowable cost for costs incurred for non-host governmental entities operating where no
applicable tax exemption exists. This waiver does not apply to countries where a bilateral
agreement (or similar legal document) is already in place providing applicable tax exemptions
and it is not applicable to Ministries of Health. Successful applicants will receive information on
VAT requirements via their Notice of Award.
B. The U.S. Department of State requires that agencies collect and report information on the
amount of taxes assessed, reimbursed and not reimbursed by a foreign government against
commodities financed with funds appropriated by the U.S. Department of State, Foreign
Operations and Related Programs Appropriations Act (SFOAA) (“United States foreign
assistance funds”). Outlined below are the specifics of this requirement:
1) Annual Report: The recipient must submit a report on or before November 16 for each foreign
country on the amount of foreign taxes charged, as of September 30 of the same year, by a
foreign government on commodity purchase transactions valued at 500 USD or more financed
with United States foreign assistance funds under this grant during the prior United States fiscal
year (October 1 – September 30), and the amount reimbursed and unreimbursed by the foreign
government. [Reports are required even if the recipient did not pay any taxes during the reporting
period.]
2) Quarterly Report: The recipient must quarterly submit a report on the amount of foreign taxes
charged by a foreign government on commodity purchase transactions valued at 500 USD or
more financed with United States foreign assistance funds under this grant. This report shall be
submitted no later than two weeks following the end of each quarter: April 15, July 15, October
15 and January 15.
3) Terms: For purposes of this clause:
“Commodity” means any material, article, supplies, goods, or equipment;
“Foreign government” includes any foreign government entity;
“Foreign taxes” means value-added taxes and custom duties assessed by a foreign government
on a commodity. It does not include foreign sales taxes.
4) Where: Submit the reports to the Director and Deputy Director of the CDC office in the
country(ies) in which you are carrying out the activities associated with this cooperative
Page 53 of 61
agreement. In countries where there is no CDC office, send reports to VATreporting@cdc.gov.
5) Contents of Reports: The reports must contain:
a. recipient name;
b. contact name with phone, fax, and e-mail;
c. agreement number(s) if reporting by agreement(s);
d. reporting period;
e. amount of foreign taxes assessed by each foreign government;
f. amount of any foreign taxes reimbursed by each foreign government;
g. amount of foreign taxes unreimbursed by each foreign government.
6) Subagreements. The recipient must include this reporting requirement in all applicable
subgrants and other subagreements.
6. Termination
CDC may impose other enforcement actions in accordance with 45 CFR 75.371- Remedies for
Noncompliance, as appropriate.
The Federal award may be terminated in whole or in part as follows:
(1) By the HHS awarding agency or pass-through entity, if the non-Federal entity fails to comply
with the terms and conditions of the award;
(2) By the HHS awarding agency or pass-through entity for cause;
(3) By the HHS awarding agency or pass-through entity with the consent of the non-Federal
entity, in which case the two parties must agree upon the termination conditions, including the
effective date and, in the case of partial termination, the portion to be terminated; or
(4) By the non-Federal entity upon sending to the HHS awarding agency or pass-through entity
written notification setting forth the reasons for such termination, the effective date, and, in the
case of partial termination, the portion to be terminated. However, if the HHS awarding agency
or pass-through entity determines in the case of partial termination that the reduced or modified
portion of the Federal award or subaward will not accomplish the purposes for which the Federal
award was made, the HHS awarding agency or pass-through entity may terminate the Federal
award in its entirety.
G. Agency Contacts
CDC encourages inquiries concerning this notice of funding opportunity.
Program Office Contact
For programmatic technical assistance, contact:
First Name:
Rebekah
Last Name:
Page 54 of 61
Buckley
Project Officer
Department of Health and Human Services
Centers for Disease Control and Prevention
Address:
Telephone:
Email:
InnovativeCVH@cdc.gov
Grants Staff Contact
For financial, awards management, or budget assistance, contact:
First Name:
Keisha
Last Name:
Thompson
Grants Management Specialist
Department of Health and Human Services
Office of Grants Services
Address:
Telephone:
Email:
dwt6@cdc.gov
For assistance with submission difficulties related to www.grants.gov, contact the Contact
Center by phone at 1-800-518-4726.
Hours of Operation: 24 hours a day, 7 days a week, except on federal holidays.
CDC Telecommunications for persons with hearing loss is available at: TTY 1-888-232-6348
H. Other Information
Following is a list of acceptable attachments applicants can upload as PDF files as part of their
application at www.grants.gov. Applicants may not attach documents other than those listed; if
other documents are attached, applications will not be reviewed.
Project Abstract
Project Narrative
Budget Narrative
Report on Programmatic, Budgetary and Commitment Overlap
Table of Contents for Entire Submission
For international NOFOs:
Page 55 of 61
SF424
SF424A
Funding Preference Deliverables
Optional attachments, as determined by CDC programs:
Resumes / CVs
Letters of Support
Organization Charts
Indirect Cost Rate, if applicable
Memorandum of Agreement (MOA)
Memorandum of Understanding (MOU)
Bona Fide Agent status documentation, if applicable
I. Glossary
Activities: The actual events or actions that take place as a part of the program.
Administrative and National Policy Requirements, Additional Requirements
(ARs): Administrative requirements found in 45 CFR Part 75 and other requirements mandated
by statute or CDC policy. All ARs are listed in the Template for CDC programs. CDC programs
must indicate which ARs are relevant to the NOFO; recipients must comply with the ARs listed
in the NOFO. To view brief descriptions of relevant provisions,
see .https://www.cdc.gov/grants/additional-requirements/index.html. Note that 2 CFR 200
supersedes the administrative requirements (A-110 & A-102), cost principles (A-21, A-87 & A122) and audit requirements (A-50, A-89 & A-133).
Approved but Unfunded: Approved but unfunded refers to applications recommended for
approval during the objective review process; however, they were not recommended for funding
by the program office and/or the grants management office.
Assistance Listings: A government-wide collection of federal programs, projects, services, and
activities that provide assistance or benefits to the American public.
Assistance Listings Number: A unique number assigned to each program and NOFO
throughout its lifecycle that enables data and funding tracking and transparency
Award: Financial assistance that provides support or stimulation to accomplish a public purpose.
Awards include grants and other agreements (e.g., cooperative agreements) in the form of
money, or property in lieu of money, by the federal government to an eligible applicant.
Budget Period or Budget Year: The duration of each individual funding period within the
project period. Traditionally, budget periods are 12 months or 1 year.
Carryover: Unobligated federal funds remaining at the end of any budget period that, with the
approval of the GMO or under an automatic authority, may be carried over to another budget
period to cover allowable costs of that budget period either as an offset or additional
authorization. Obligated but liquidated funds are not considered carryover.
Page 56 of 61
Competing Continuation Award: A financial assistance mechanism that adds funds to a grant
and adds one or more budget periods to the previously established period of performance (i.e.,
extends the “life” of the award).
Continuous Quality Improvement: A system that seeks to improve the provision of services
with an emphasis on future results.
Contracts: An award instrument used to acquire (by purchase, lease, or barter) property or
services for the direct benefit or use of the Federal Government.
Cooperative Agreement: A financial assistance award with the same kind of interagency
relationship as a grant except that it provides for substantial involvement by the federal agency
funding the award. Substantial involvement means that the recipient can expect federal
programmatic collaboration or participation in carrying out the effort under the award.
Cost Sharing or Matching: Refers to program costs not borne by the Federal Government but
by the recipients. It may include the value of allowable third-party, in-kind contributions, as well
as expenditures by the recipient.
Direct Assistance: A financial assistance mechanism, which must be specifically authorized by
statute, whereby goods or services are provided to recipients in lieu of cash. DA generally
involves the assignment of federal personnel or the provision of equipment or supplies, such as
vaccines. DA is primarily used to support payroll and travel expenses of CDC employees
assigned to state, tribal, local, and territorial (STLT) health agencies that are recipients of grants
and cooperative agreements. Most legislative authorities that provide financial assistance to
STLT health agencies allow for the use of DA. https://www.cdc.gov/grants/additionalrequirements/index.html.
Evaluation (program evaluation): The systematic collection of information about the activities,
characteristics, and outcomes of programs (which may include interventions, policies, and
specific projects) to make judgments about that program, improve program effectiveness, and/or
inform decisions about future program development.
Evaluation Plan: A written document describing the overall approach that will be used to guide
an evaluation, including why the evaluation is being conducted, how the findings will likely be
used, and the design and data collection sources and methods. The plan specifies what will be
done, how it will be done, who will do it, and when it will be done. The NOFO evaluation plan is
used to describe how the recipient and/or CDC will determine whether activities are
implemented appropriately and outcomes are achieved.
Federal Funding Accountability and Transparency Act of 2006 (FFATA): Requires that
information about federal awards, including awards, contracts, loans, and other assistance and
payments, be available to the public on a single website at www.USAspending.gov.
Fiscal Year: The year for which budget dollars are allocated annually. The federal fiscal year
starts October 1 and ends September 30.
Grant: A legal instrument used by the federal government to transfer anything of value to a
recipient for public support or stimulation authorized by statute. Financial assistance may be
money or property. The definition does not include a federal procurement subject to the Federal
Acquisition Regulation; technical assistance (which provides services instead of money); or
Page 57 of 61
assistance in the form of revenue sharing, loans, loan guarantees, interest subsidies, insurance, or
direct payments of any kind to a person or persons. The main difference between a grant and a
cooperative agreement is that in a grant there is no anticipated substantial programmatic
involvement by the federal government under the award.
Grants.gov: A "storefront" web portal for electronic data collection (forms and reports) for
federal grant-making agencies at www.grants.gov.
Grants Management Officer (GMO): The individual designated to serve as the HHS official
responsible for the business management aspects of a particular grant(s) or cooperative
agreement(s). The GMO serves as the counterpart to the business officer of the recipient
organization. In this capacity, the GMO is responsible for all business management matters
associated with the review, negotiation, award, and administration of grants and interprets grants
administration policies and provisions. The GMO works closely with the program or project
officer who is responsible for the scientific, technical, and programmatic aspects of the grant.
Grants Management Specialist (GMS): A federal staff member who oversees the business and
other non-programmatic aspects of one or more grants and/or cooperative agreements. These
activities include, but are not limited to, evaluating grant applications for administrative content
and compliance with regulations and guidelines, negotiating grants, providing consultation and
technical assistance to recipients, post-award administration and closing out grants.
Health Disparities: Differences in health outcomes and their determinants among segments of
the population as defined by social, demographic, environmental, or geographic category.
Health Equity: Striving for the highest possible standard of health for all people and giving
special attention to the needs of those at greatest risk of poor health, based on social conditions.
Health Inequities: Systematic, unfair, and avoidable differences in health outcomes and their
determinants between segments of the population, such as by socioeconomic status (SES),
demographics, or geography.
Healthy People 2030: National health objectives aimed at improving the health of all Americans
by encouraging collaboration across sectors, guiding people toward making informed health
decisions, and measuring the effects of prevention activities.
Inclusion: Both the meaningful involvement of a community’s members in all stages of the
program process and the maximum involvement of the target population that the intervention
will benefit. Inclusion ensures that the views, perspectives, and needs of affected communities,
care providers, and key partners are considered.
Indirect Costs: Costs that are incurred for common or joint objectives and not readily and
specifically identifiable with a particular sponsored project, program, or activity; nevertheless,
these costs are necessary to the operations of the organization. For example, the costs of
operating and maintaining facilities, depreciation, and administrative salaries generally are
considered indirect costs.
Letter of Intent (LOI): A preliminary, non-binding indication of an organization’s intent to
submit an application.
Lobbying: Direct lobbying includes any attempt to influence legislation, appropriations,
regulations, administrative actions, executive orders (legislation or other orders), or other similar
Page 58 of 61
deliberations at any level of government through communication that directly expresses a view
on proposed or pending legislation or other orders, and which is directed to staff members or
other employees of a legislative body, government officials, or employees who participate in
formulating legislation or other orders. Grass roots lobbying includes efforts directed at inducing
or encouraging members of the public to contact their elected representatives at the federal, state,
or local levels to urge support of, or opposition to, proposed or pending legislative proposals.
Logic Model: A visual representation showing the sequence of related events connecting the
activities of a program with the programs’ desired outcomes and results.
Maintenance of Effort: A requirement contained in authorizing legislation, or applicable
regulations that a recipient must agree to contribute and maintain a specified level of financial
effort from its own resources or other non-government sources to be eligible to receive federal
grant funds. This requirement is typically given in terms of meeting a previous base-year dollar
amount.
Memorandum of Understanding (MOU) or Memorandum of Agreement
(MOA): Document that describes a bilateral or multilateral agreement between parties
expressing a convergence of will between the parties, indicating an intended common line of
action. It is often used in cases where the parties either do not imply a legal commitment or
cannot create a legally enforceable agreement.
Nonprofit Organization: Any corporation, trust, association, cooperative, or other organization
that is operated primarily for scientific, educational, service, charitable, or similar purposes in the
public interest; is not organized for profit; and uses net proceeds to maintain, improve, or expand
the operations of the organization. Nonprofit organizations include institutions of higher
educations, hospitals, and tribal organizations (that is, Indian entities other than federally
recognized Indian tribal governments).
Notice of Award (NoA): The official document, signed (or the electronic equivalent of
signature) by a Grants Management Officer that: (1) notifies the recipient of the award of a grant;
(2) contains or references all the terms and conditions of the grant and Federal funding limits and
obligations; and (3) provides the documentary basis for recording the obligation of Federal funds
in the HHS accounting system.
Objective Review: A process that involves the thorough and consistent examination of
applications based on an unbiased evaluation of scientific or technical merit or other relevant
aspects of the proposal. The review is intended to provide advice to the persons responsible for
making award decisions.
Outcome: The results of program operations or activities; the effects triggered by the program.
For example, increased knowledge, changed attitudes or beliefs, reduced tobacco use, reduced
morbidity and mortality.
Performance Measurement: The ongoing monitoring and reporting of program
accomplishments, particularly progress toward pre-established goals, typically conducted by
program or agency management. Performance measurement may address the type or level of
program activities conducted (process), the direct products and services delivered by a program
(outputs), or the results of those products and services (outcomes). A “program” may be any
activity, project, function, or policy that has an identifiable purpose or set of objectives.
Page 59 of 61
Period of performance –formerly known as the project period - : The time during which the
recipient may incur obligations to carry out the work authorized under the Federal award. The
start and end dates of the period of performance must be included in the Federal award.
Period of Performance Outcome: An outcome that will occur by the end of the NOFO's
funding period
Plain Writing Act of 2010: The Plain Writing Act of 2010 requires that federal agencies use
clear communication that the public can understand and use. NOFOs must be written in clear,
consistent language so that any reader can understand expectations and intended outcomes of the
funded program. CDC programs should use NOFO plain writing tips when writing NOFOs.
Program Strategies: Strategies are groupings of related activities, usually expressed as general
headers (e.g., Partnerships, Assessment, Policy) or as brief statements (e.g., Form partnerships,
Conduct assessments, Formulate policies).
Program Official: Person responsible for developing the NOFO; can be either a project officer,
program manager, branch chief, division leader, policy official, center leader, or similar staff
member.
Public Health Accreditation Board (PHAB): A nonprofit organization that works to promote
and protect the health of the public by advancing the quality and performance of public health
departments in the U.S. through national public health department
accreditation http://www.phaboard.org.
Social Determinants of Health: Conditions in the environments in which people are born, live,
learn, work, play, worship, and age that affect a wide range of health, functioning, and qualityof-life outcomes and risks.
Statute: An act of the legislature; a particular law enacted and established by the will of the
legislative department of government, expressed with the requisite formalities. In foreign or civil
law any particular municipal law or usage, though resting for its authority on judicial decisions,
or the practice of nations.
Statutory Authority: Authority provided by legal statute that establishes a federal financial
assistance program or award.
System for Award Management (SAM): The primary vendor database for the U.S. federal
government. SAM validates applicant information and electronically shares secure and encrypted
data with federal agencies' finance offices to facilitate paperless payments through Electronic
Funds Transfer (EFT). SAM stores organizational information, allowing www.grants.gov to
verify identity and pre-fill organizational information on grant applications.
Technical Assistance: Advice, assistance, or training pertaining to program development,
implementation, maintenance, or evaluation that is provided by the funding agency.
UEI: The Unique Entity Identifier (UEI) number is a twelve-digit number assigned by
SAM.gov. When applying for Federal awards or cooperative agreements, all applicant
organizations must obtain a UEI number as the Universal Identifier. UEI number assignment is
free. If an organization does not know its UEI number or needs to register for one, visit
www.sam.gov.
Page 60 of 61
Work Plan: The summary of period of performance outcomes, strategies and activities,
personnel and/or partners who will complete the activities, and the timeline for completion. The
work plan will outline the details of all necessary activities that will be supported through the
approved budget.
NOFO-specific Glossary and Acronyms
Page 61 of 61
| File Type | application/pdf |
| Author | Adetayo, Kemi (NIH/OD) [C] |
| File Modified | 2018-08-24 |
| File Created | 2016-12-20 |